Design and Evaluation of Gastro Retentive Floating Drug Delivery System of Valsartan. by Yuganya, B
 DESIGN AND EVALUATION OF GASTRO RETENTIVE 
FLOATING DRUG DELIVERY SYSTEM OF VALSARTAN 
 
Dissertation submitted to 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY, 
CHENNAI. 
In partial fulfillment of the requirement  
for the award of the degree of 
 
MASTER OF PHARMACY 
 
Submitted by 
(Reg. No: 26108610) 
 
 
 
 
DEPARTMENT OF PHARMACEUTICS 
COLLEGE OF PHARMACY 
MADURAI MEDICAL COLLEGE  
MADURAI – 625 020. 
 
MAY - 2012 
 Dr. Mrs. AJITHADAS ARUNA, M.Pharm., Ph. D.,  
Principal,  
College of Pharmacy, 
Madurai Medical College, 
Madurai-625 020. 
 
 
CERTIFICATE 
 This is to certify that the dissertation entitled “DESIGN AND EVALUATION 
OF GASTRO RETENTIVE FLOATING DRUG DELIVERY SYSTEM OF 
VALSARTAN” submitted by Miss. B. YUGANYA in partial fulfillment of the 
requirement for the Degree of Master of Pharmacy in Pharmaceutics is a bonafide 
work carried out by her, under the guidance and supervision of Prof. Mr. A. Abdul 
Hasan Sathali, M.Pharm., (Ph.D)., Professor and Head, in the Department of 
Pharmaceutics, Madurai Medical College, Madurai-20, during the academic year       
2011 – 2012. This dissertation is forwarded to the Controller of Examination, The 
Tamilnadu Dr. M.G.R. Medical University, Chennai. 
 
 
 
 
 
 
 
Place: Madurai                                                                              (AJITHADAS ARUNA) 
Date: 
 
 
  
Prof. Mr. A. ABDUL HASAN SATHALI, M.Pharm., (Ph.D).,  
Professor& Head, 
Department of Pharmaceutics, 
College of Pharmacy, 
Madurai Medical College, 
Madurai-625020 
 
 
CERTIFICATE 
 This is to certify that the dissertation entitled “DESIGN AND EVALUATION 
OF GASTRO RETENTIVE FLOATING DRUG DELIVERY SYSTEM OF 
VALSARTAN” submitted by Miss. B. YUGANYA in partial fulfillment of the 
requirement for the Degree of Master of Pharmacy in Pharmaceutics is a bonafide 
work carried out by her, under my guidance and supervision during the academic year 
2011 – 2012 in the Department of Pharmaceutics, Madurai Medical College, Madurai. 
 
I wish her success in all his endeavors. 
 
 
 
 
 
 
 
 
 
Place: Madurai                                                          (Prof. Mr. A. Abdul Hasan Sathali) 
Date:  
ACKNOWLEDGEMENT 
 
“Lives of great men all remind us 
We can make our lives sublime 
And departing leave behind us 
Foot prints on the sands of time” 
 
♣ Words are not just enough to express my gratitude to the LORD ALMIGHTY who 
directed me throughout the work. 
♣ I humbly present this work to the external ALMIGHTY.  Indeed my project is a 
small work done with the help of primitive persons at heart so it is my bounded 
duty to promulgate them individually. 
♣ I thank almighty who has been with me throughout the dissertation work and 
helped me for successful completion of my work. 
 
♣ It is my pleasure to express my respectful regards and thanks to                        
Dr .Mr..A.Edwin Joe, M.D., F.M., B.L.,  Dean, Madurai Medical College, 
Madurai for providing all kinds of supportive facilities required to carry out my 
project work. 
 
♣ It is my privilege to extend my gratitude to Dr. Mrs. Ajithadas Aruna, M.Pharm., 
Ph. D., Principal, College of pharmacy, Madurai Medical College, Madurai for 
her support to carry out my project work. 
 
♣ It is my immense pleasure and honour to express my deep sense of gratitude and 
heartfelt thanks to Prof. Mr. A. Abdul Hasan Sathali, M.Pharm., (Ph. D)., 
Professor and  Head, Department of Pharmaceutics for his excellence in 
guidance, contribution and encouragement which helped me in the successful 
completion of each and every stage of my project work. 
 ♣ With immense pleasure I record here my indebtness and hearty thanks to                      
Mr. C. Pandian, M.Pharm., Mrs. D. Uma Maheswari, M.Pharm., and                        
Mr. R. Senthil Prabhu, M.Pharm., Department of Pharmaceutics for his support 
and valuable suggestions throughout my work. 
 
♣ I also extend my thanks to our department staffs Mrs. Mumtaj, Mrs. Geetha and 
Mrs.Chitravalli for their contribution throughout my project work. 
 
♣ I take this privilege to convey my thanks to Mrs.Manimegalai M.Sc.,M.Phil., 
Technical officer USIC – M.K.University, Madurai and St. Joseph’s College, 
Trichy for her helping to carry out FT - IR studies in accordance with my 
dissertation work.  
 
♣ I convey my sincere thanks to JSS College of Pharmacy, Ooty for their help in 
carrying out the DSC studies in accordance with my dissertation work. 
 
♣ My sincere thanks to ATOZ Pharmaceuticals, Chennai for their help in carrying 
out the HPLC studies in accordance with my dissertation work. 
 
♣ I wish to acknowledge Mr. Raja, Karunya University, Coimbatore, for his help in 
SEM Studies in accordance with my Dissertation work. 
 
♣ I am very much thankful to Mrs. Lavanya Anbu, Pharma Information Centre, 
Chennai, for her help in reference collections regarding my project. 
♣ I extend my thanks to Dr. Mr. Jonat, M.V.S.C., Veterinary Assistant Surgeon, 
Central Animal House, Madurai Medical College, Madurai for his valuable 
assistance during invivo studies. 
♣ I wish to thank Mr. Shanmugam, Madurai Digital X-Rays, for their timely help 
to carry out my X-Ray studies. 
 
♣ I convey my sincere thanks to Mr. S. Petchimuthu, M. Pharm., Shashun Pharm, 
Pondicherry and Mr. S. Abdul Kadar, B. Pharm., Tablets India, Chennai for 
providing polymers to carry out my project work. 
 
♣ I express my heartiest thanks to Mr.Sampath, B.Pharm., &                           
Mr. G. Manikandan, B. Pharm., Dr. Reddys Pharmaceuticals, Ranbaxy Pharm 
and Tablets India, Chennai  for providing the drug Valsartan as gift sample to 
carry and United Scientifics and universal drug & chemical suppliers for 
providing chemicals to carry out my project work. 
 
♣ It is pleasure to express my thanks to my seniors Ms.A.Gokila, Mrs.R.Kavitha, 
Ms.K.Priyanka, Ms. P. Shanmugapriya and Ms.T.Sangeetha for their moral 
support. 
 
 
♣ Also I would like to extend my sincere thanks to my friends Mr.S.Ganesan 
Mr.S.Kathiravan, Mr.V.Palanivel, Mr.T.Prakash, Mr.D.RajivGandhi, 
Mr.V.Selvaraj, Ms.R.Revathi, Ms.T.Suganya & Mr.J.Varun  for their moral 
support. 
 
♣ I would like to give my sincere thanks to my juniors Ms. C. Deepa.,                   
Ms. M. Gomathi.,  Ms. V.Susila devi., Mrs. J. Jayalakshmi., Ms N.Surya devi.,  
Ms. N. Nisha., Mr. L. Magesh kumar., Mr. I. Samdurai.,  Mr. P.Mainkandan., 
& Mr. M. Gopinath for their timely help and co-operation. 
 
♣ I also extend my thanks to all the staff members and P.G. Students of Department 
of Pharmaceutical Chemistry and Pharmacognosy for their Co-operation. 
 
♣ I am extremely thankful to the staffs of Laser Point, for their kind co-operation 
regarding printing and binding of this dissertation work.          
 
♣ I honestly acknowledge the love, care and moral support rendered by my family 
members & friends whose part cannot be expressed in holophrastic. 
 
 
CONTENTS  
 
CHAPTER 
NO 
TITLE 
PAGE 
NO 
I INTRODUCTION 1 
II 
GASTRORETENTIVE  DRUG DELIVERY 
SYSTEM- A REVIEW 
23 
III 
FLOATING DRUG DELIVERY SYSTEM 
– A REVIEW  
41 
IV LITERATURE REVIEW 60 
V AIM & OBJECTIVE OF THE WORK 74 
VI PLAN OF WORK 76 
VII MATERIALS AND EQUIPMENTS 79 
VIII DRUG PROFILE 81 
IX EXCIPIENTS PROFILE 88 
X EXPERIMENTAL PROTOCOL 101 
XI 
RESULTS AND DISCUSSION 
TABLES & FIGURES 
115 
XII SUMMARY AND CONCLUSION 130 
 REFERENCES 
 
 Annexure I 
 
 Annexure II 
 
 
CHAPTER I                                                                     INTRODUCTION  
 
FLOATING DRUG DELIVERY SYSTEM Page 1 
 
CHAPTER – I 
INTRODUCTION 
For decades an acute condition or chronic illness is being clinically treated 
through delivery of drugs to the patients in form of some pharmaceutical dosage forms 
like tablets, capsules, creams, liquids, ointments, aerosols, etc. 
To attain and maintain the concentration of an administered drug within 
therapeutically effective range, it is often required to take drug dosage several times and 
this result in a fluctuating drug level in plasma. Controlled or sustained drug delivery 
systems have been introduce to overwhelm the problem of fluctuating drug levels related 
with conventional dosage forms (Vyas.S.P & Khar, 2002) , as shown in Figure 1 
(Jaiswal.S.B et al., 2007). 
Fundamentally, there are three modes of drug delivery which are, 
 SUSTAINED RELEASE DRUG DELIVERY SYSTEM  
 CONTROLLED RELEASE DRUG DELIVERY SYSTEM 
 TARGETED DRUG DELIVERY SYSTEMS  
CONVENTIONAL DRUG DELIVERY SYSTEM  
Conventional drug delivery system is known to provide a prompt release of drug; 
therefore, to attain as well as to maintain the drug concentration within the therapeutically 
effective range needed for treatment, it is often necessary to take these types of drug 
delivery system several times a day. This result in a significant fluctuation in drug levels              
(Chien Y.W, 1982; Jaiswal.S.B et al., 2007).  
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Figure 1: Plasma drug concentration-time profile for conventional dosage 
formulation, a sustained release formulation and a zero order                       
controlled delivery formulation. 
Drawbacks of Conventional Dosage Forms: 
 Poor patient compliance 
 Increased chances of missing the dose of a drug 
 Shorter half life 
 To attain steady-state plasma concentration is difficult. 
 Fluctuations in drug levels (Shalin A. Modi et al., 2011; Chien Y.W, 1992). 
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A) SUSTAINED RELEASE DRUG DELIVERY  
Sustained release drug delivery system, which means the release of active agent is 
slower than any conventional formulation, but is significantly affected by an external 
environment. The onset of its pharmacological action is delayed, and the duration of 
therapeutic effect is sustained. That means, to retard the release of a therapeutic agent in 
the systemic circulation is delayed and/or prolonged and its plasma profile is sustained 
(Jaiswal.S.B et al., 2007; Shalin A. Modi et al., 2011). 
B) CONTROLLED RELEASE DRUG DELIVERY SYSTEM  
Controlled release systems provide a release profile independent of external 
environment and predominantly controlled by the design of the system. It implies a 
predictability and reproducibility in the drug release kinetics. That means, the release of 
drug ingredient(s) from a controlled-release drug delivery system proceeds at a rate 
profile that is predictable kinetically, and also  reproducible from one unit to another 
(Xiaoling Li et al., 2005; Brahmankar D.M et al., 1995). 
The plasma level of drug should be maintained within the safe margin and 
effective range, for this proper and calculated dose of the drug need to be given at 
different time intervals by conventional dosage forms (Shalin A. Modi et al., 2011). 
C) TARGETED DRUG DELIVERY SYSTEM  
Targeted delivery refers to the systemic administration of a drug carrier with the 
goal of delivering the drug to specific cell types, tissues, or organs. 
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 The distribution of other tissues seems unnecessary, and a potential cause of 
toxicity. Most of diseases treated by cytotoxic agents not only demand for controlled drug 
delivery but also the pattern of delivery is directed to be specific, precise and defined at 
quantitative levels. 
The legend-receptor interactions are highly stereo specific. Thus ligands or 
receptors could be exploited for site/cell specific drug delivery quantitatively in a well 
defined manner. 
Approaches are being adopted either to control the distribution of drug by 
incorporating it in a carrier or altering the structure of the drug at the molecular level, or 
by controlling the input of the drug into the bioenvironmental to ensure a programmed 
and desirable biodistribution (Vyas.S.P & Khar, 2002). 
RATIONALE OF SUSTAINED, CONTROLLED AND TARGETED DRUG 
DELIVERY: 
The drug delivery system are usually known by terms like sustained, controlled, 
targeted, novel, and therapeutic and programmed. However, the basic rationale for these 
varied delivery modules is the alteration or manipulation of pharmacokinetic and 
pharmacodynamic of pharmacologically active moieties. This can be achieved either by 
using novel delivery devices (like Liposome, Transdermal patches or Matrix or 
Membrane controlled devices) , or by modifying the structure in molecular level (Prodrug 
or Chemical delivery system) and/or physiological parameters inherent by route of 
administration selected (like rectal route to avoid first pass metabolism). A drug delivery 
system may be thought of as one in which three components are included: the drug input 
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function: the pharmacokinetic responses (metabolism): and the pharmacodynamic 
responses (therapeutic and side effects) (Xiaoling Li et al., 2005; Brahmankar D.M et al., 
2002). 
It is important to critically evaluate different terms used under broad category of 
novel drug delivery systems: 
 Sustained or controlled drug delivery systems provide drug action at a 
predetermined rate by providing a prolonged or constant (zero-order) release 
respectively, at therapeutically effective levels in the circulation. 
 Localized drug delivery devices through spatial or temporal control of drug 
release (usually rate-limiting) in the vicinity of the target. 
 Rate-preprogrammed drug delivery systems, by the release of drug molecules by 
system design, which controls the molecular diffusion of drug molecules. Fick’s 
laws of diffusion are followed. 
 Targeted drug delivery by using carriers either meant for passive preprogrammed 
or active preprogrammed or self-programmed approach or usually appended with 
suitable site-directing molecules which recognize their receptor or carbohydrate 
determinants at the target. 
RECENT DEVELOPMENTS 
 
 
Controlled-released formulations have been widely developed and marketed over 
the past 30years under various terms such as sustained release, prolonged-release, timed-
release, or other similar names that are often ill-defined and misleading.     
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Recently, a number of novel drug delivery systems that uses unique concepts have 
been studied intensively. Some of the strategies include targeted delivery, self-regulated 
release, biofeedback mechanisms, and drug attached to biological carriers (Vyas.S.P & 
Khar, 2002; Xiaoling Li et al., 2005). 
 Controlled-release formulations can be designed for any route of administrations 
as follows: 
 Oral 
 Parenteral 
 Implants 
 Transdermal 
 Other routes: ocular, nasal, vaginal, etc. 
The development of improved controlled-release and novel drug delivery systems 
will have significant implications for achieving more effective drug therapy.    
The most preferred route of drug administration for systemic delivery of drugs is 
orally. More than 50% of drug delivery systems available in the market are oral drug 
delivery systems. These systems have the obvious advantages of case of administration 
and patient acceptance. Several oral drug delivery technologies have come and gone, and 
new systems still emerge even today. 
 One would always like to have ideal drug delivery systems that will possess two 
main properties,  
1. It will be a single dose for the whole duration of treatment 
2. It will deliver the active drug directly at the site of action.  
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It offers advantages like, 
 
 Patient compliance 
 Flexibility in formulation 
 Ease of administration 
Reasons for Interest in New DDS 
 Improving conventional dosage forms 
 Exclusivity for existing drugs 
 High cost for developing new drugs 
 Delivery of bioengineered compounds 
 Enhanced efficacy and safety 
Some of the potential benefits and drawbacks of controlled-release and novel drug 
delivery systems are as follows: 
Potential Benefits of Novel Drug Delivery System 
 Convenience in dosing 
 Higher patient compliance 
 Better utilization of drugs  
 Reduced adverse effects 
 Improved efficacy 
Potential Problems of Novel Drug Delivery 
 Delivery of drugs to the target tissues/organs 
 Extravasations of drugs/carriers in the tissues/organs 
 Liberation of drugs from the carrier 
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 Penetration into specific cells/cell components 
 Control of residence time at the receptor site. 
ORAL CONTROLLED RELEASE FORMULATIONS 
Oral route has been the commonly selected and most suitable for the drug 
delivery. Oral route of administration has more attention in the pharmaceutical field 
because of the more flexibility in the designing of dosage form than other routes of drug 
delivery (Stanley S.Davies et al., 2005; Shalin A. Modi et al., 2011).  
The oral controlled drug delivery systems are mostly solids and based on 
diffusion, dissolution or combination of both mechanisms in the control of release rate of 
drug.  
Novel oral drug delivery systems are broadly classified into two categories as they 
may control release dosage forms as well as targeting dosage forms. General controlled 
manner in the GIT for systemic uptake and no particular area of GIT specified. In 
contrast, targeted preparations are releasing the drug in a specified area or tissue of the GI 
(e.g. floating drug delivery system). 
Targeting systems are either releasing drug in controlled manner or in one burst at 
the specific area. The goal of a targeted oral drug delivery system (TODDS) is to achieve 
better therapeutics success compared to conventional dosage form. This can be achieved 
by improving the pharmacokinetic profile, patient convenience and compliance in therapy 
(Stanley S.Davies et al., 2005). 
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Advantages of TODDS 
 Reduced dosing frequency 
 Better patient convenience and compliance 
 Reduced GI side effects and other toxic effects. 
 Less fluctuating plasma drug level 
 More uniform drug effect 
 Less total dose 
 Better stability of the drug (Brahmankar D.M et al., 1995; Vyas S.P & Khar, 
2002). 
 Disadvantages of TODDS: 
 Higher cost 
 Relatively poor in vitro-in vivo correlation 
 Possible dose dumping  
 Reduced potential for dose change or withdrawal in the event of toxicity 
(Brahmankar D.M et al., 1995). 
Targeting of drugs through oral route involves control of time of release or 
location of release. On the basis of environmental, anatomical and physiological factors 
these drug delivery system can be classified with respect to target site as follows: 
 Systems targeted to stomach/duodenum 
 Systems targeted to small intestine 
 Systems targeted to large intestine/colon 
 Systems targeted to lymphatic. 
CHAPTER I                                                                     INTRODUCTION  
 
FLOATING DRUG DELIVERY SYSTEM Page 10 
 
ORAL DIFFUSION-CONTROLLED SYSTEM
  
 
The basic concepts of oral controlled release dosage forms can be defined based 
on release-profile characteristic or the underlying release- controlling mechanism. Two 
distinct drug release profiles, extended and delayed release, are achievable, and they can 
be used in various combinations to provide the desired release rate. Three delivery 
systems dominate today’s market of oral CR products: 
 Matrix systems, 
 Reservoir  systems and 
 Osmotic systems. 
             Release mechanisms from these dosage forms, diffusion plays a key role in both 
matrix and reservoir systems, whereas osmotic pressure is the predominant mechanism of 
drug release from osmotic systems and could also play a role in a reservoir system         
(Shalin A. Modi et al., 2011). 
A) Matrix systems 
A matrix system consists of active and inactive ingredients that are 
homogeneously mixed in the dosage form. Matrix systems divide into two categories, 
based on rate-controlling materials (Shalin A. Modi et al., 2011). 
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Figure 2: Matrix (“Monolithic”) DDS 
 Hydrophobic matrix systems 
 Hydrophilic matrix systems  
1. Hydrophobic matrix systems 
This is the only system where use of a polymer is not essential to provide 
controlled drug release, although insoluble polymers have been used. As the term 
suggests, the primary rate-controlling components of a hydrophobic matrix are water 
insoluble in nature. These ingredients include waxes, glycerides, fatty acids, and 
polymeric materials such as ethyl cellulose and methacrylate copolymers. To modulate 
drug release, it is necessary to incorporate soluble ingredients such as lactose into the 
formulation. 
The presence of insoluble ingredients in the formulations helps to maintain the 
physical dimension of a hydrophobic matrix during drug release. Diffusion of the active 
form from the system is the release mechanism. Very often, pores form within a 
hydrophobic matrix as a result of the release of the active ingredient. Hydrophobic matrix 
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systems generally are not suitable for insoluble drugs because the concentration gradient 
is too low to render drug release. 
2. Hydrophilic matrix systems  
The primary rate-controlling ingredients of a hydrophilic matrix are polymers that 
would swell on contact with the aqueous solution and form a gel layer on the surface of 
the system. 
Drugs release from hydrophilic matrices is by polymer dissolution (erosion) and 
diffusion of drug molecules across the gel layer have been identified as the                   
rate-controlling mechanisms.  
The model semi empirical “exponent equation” has been used widely to 
differentiate the contributions of both mechanisms: 
Qt =kt
n
 
Where Qt is amount Q in time t, n is a diffusion exponent, and k is a kinetic 
constant. If diffusion dominates polymer erosion, the value of n would approach 0.5. On 
the other hand, for erosion-controlled formulations, n would approach the value of unity. 
Under an “anomalous” condition, the value of n falls in between 0.5 and 1 when both 
diffusion and erosion play roles.  
More recently, a “spaghetti” model (Figure 3) for a swollen matrix was developed 
to provide mechanistic understanding of the complex release process. This model treats 
polymer erosion as diffusion of polymer across a “diffusion layer” adjacent to the gel 
layer. Thus two competitive diffusion processes contribute to overall drug release: 
diffusion of polymer across the diffusion layer and diffusion of drug across the gel layer. 
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Figure 3: Spaghetti model for a swollen matrix 
 For very soluble compounds, diffusion of drug molecules is the dominant 
mechanism of release, and the role of polymer erosion is limited in modulating drug 
release. Thus, developing a hydrophilic matrix for highly soluble drugs that requires 
prolonged release (e.g., >12 h) can be challenging. On the other hand, release of less 
soluble drugs from hydrophilic matrices is expected to be slow because both polymer 
dissolution and drug diffusion play key roles.  
The polymers used in the preparation of hydrophilic matrices, 
1. Cellulose derivates 
2. Non-cellulose natural or semi synthetic polymers 
3. Polymers of acrylic acid. 
B) Reservoir Devices 
Reservoir devices are those in which a core of drug is surrounded by polymeric 
membrane. The nature of membrane determines the rate of release of drug from system.  
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The process of diffusion is generally described by a series of equations governed by 
Fick’s first law of diffusion (Shalin A. Modi et al., 2011).  
J = -D (dc/ dx)             (1) 
Where, 
 J = flux of drug across the membrane given in units of amount / area time.  
 D = diffusion coefficient of drug in membrane in units of area / time.  
 
Figure 4: Reservoir DDS 
This is reflecting to drug molecule’s ability to diffuse through the solvent and is 
dependent on the factors as molecular size and charge.  
 dc/ dt  = represents rate of change in concentration C relative to a distance 
X in the membrane.  
The law states that amount of drug passing across a unit area, is proportional to 
the concentration difference across that plane. 
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Figure 5: Schematic representation of reservoir diffusion device Cm (o), and Cm (d) 
represent concentration of drug inside surfaces of membrane and C (o) & C (d) 
represents concentration in adjacent regions. 
If it is assumed that the drug on the both side of membrane is in equilibrium with 
its respective membrane surface which in equilibrium between the membrane surfaces 
and their bathing solutions as shown in Figure 5.  Therefore the concentration just inside 
the membrane surface can be related to the concentration in the adjacent region by 
following expression.  
K = Cm (o) /C (d)      at X = o                                  (2) 
K = Cm (d) / C (d)     at X = d                                  (3) 
Where, 
K = Partition coefficient. 
If we consider K & D are constants then equation (1) becomes,  
      J = D K C/d                                          (4) 
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Where, 
 c is the concentration difference across the membrane and d is path 
length of diffusion.  
The simplest system to consider is that of slab, where drug release is from only 
one surface as shown Figure 6  in this case equation (4) becomes  
dMt/ dt  =    ADK C/ d                   (5) 
 
Figure 6: Diagrammatic representation of slab configuration of reservoir diffusion 
system. 
 
Non permeable polymer shell  
Where, 
 Mt = Mass of drug released after time t. 
 dMt/dt =Steady state drug release rate of time ‘t’. 
 A=surface area of device. 
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If variables of right side of equation remain constant, then left side of equation 
represents release rate of system, a true controlled release system with a zero-order 
release rate.  
A constant effective area of diffusion, diffusional path length, concentration 
difference, and diffusion coefficient are required to obtain a release rate that is constant. 
Reservoir diffusional systems have several advantages over conventional dosage forms. 
They can after zero order release of drug, kinetics of which can be controlled by changing 
the characteristics of the polymer to meet the particular drug and therapy conditions.  
 
Figure 7: Plot showing approach to steady state for reservoir device that has been 
stored for an extended period (the burst effect curve) and for device that has been 
freshly made (the time lag curve) 
Common methods used to develop reservoir type of devices include micro 
encapsulation of drug particles and press coating of tablets containing drug cores. In most 
cases particles coated by microencapsulation form a system where the drug is contained 
in the coating film as well as in the core of micro capsule. The drug release generally 
involves combination of dissolution and diffusion with dissolution being process that 
controls the release rate. If encapsulating material is selected properly will be the 
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controlling process. Some materials such as membrane barrier coat alone or in 
combination, are hardened gelatin, methyl or methylcellulose, polyhydroxymethacrylate 
hydroxypropylmethylcellulose, polyvinyl acetate & various waxes.  
ORAL DISSOLUTION CONTROLLED SYSTEM 
These types of systems are easiest to design. The drug present in such system may be 
the one (Shalin A. Modi et al., 2011): 
1. Inherently slow dissolution rate e.g. Digoxin 
2. Slow dissolving form, when it comes contact with GI fluids 
3. High aqueous solubility and dissolution rate. 
Dissolution-controlled release can be obtained by slowing the dissolution rate of a 
drug in the GI medium, incorporating the drug in an insoluble polymer material of 
varying thickness.  The rate limiting step for dissolution of a drug is the diffusion across 
the aqueous boundary layer.  The solubility of the drug provides the source of energy for 
drug release, which is countered by the stagnant-fluid diffusional boundary layer. The rate 
of dissolution can be approximated by, 
dm/dt = Ads/h 
Where, 
 S = Aqueous solubility of the drug 
 A = Surface area of the dissolving particle of tablet 
 D = Diffusivity of the drug 
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 H = Thickness of the boundary layer 
There are two drug delivery system in dissolution controlled, 
1. Matrix dissolution controlled systems 
2. Reservoir dissolution controlled systems. 
A) Matrix dissolution controlled systems: 
The drug is homogeneously dispersed throughout the rate controlling medium; 
this system is also called as monolith system.  The rate of dissolution fluid penetration 
into the matrix by altering the porosity of tablet, decreasing its wettability or by itself 
getting dissolved at a slower rate. 
B) Reservoir dissolution controlled systems: 
The drug particles are coated or encapsulated by one of the several 
microencapsulation techniques slowly dissolving materials like cellulose and PEG.  The 
dissolution rate of coat depends upon the solubility and thickness of the coating. 
Classification of oral controlled drug delivery system  
1. Continuous release system  
 
 Dissolution controlled release system 
 Diffusion controlled release system 
 Diffusion and dissolution controlled release system. 
 Ion exchange resin drug complexes 
 Slow dissolving salt and complexes 
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 pH independent formulations. 
 Osmotic pressure controlled systems 
 Hydrodynamic pressure controlled systems. 
 2.    Delayed transit and continuous release systems  
 Altered density system. 
 Mucoadhesive system. 
 Size based systems. 
       3.    Delayed Release system  
 Intestinal release system. 
 Colonic release system. 
Factors influencing the design and performance of controlled drug delivery system  
 
 Biopharmaceutical characteristic of the drug  
 Molecular weight of the drug  
 Aqueous solubility of the drug  
 Apparent partition coefficient  
 Drug pka and ionization physiological pH  
 Drug stability  
 Mechanism and site of absorption  
 Route of administration. 
 Pharmacokinetic characteristic of the drug  
 Absorption rate  
 Elimination half life  
 Rate of metabolism  
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 Dosage form index  
 Pharmacodynamic characteristic of the drug  
 Therapeutic range  
 Therapeutic index  
 Plasma–concentration–response relationship (Jain N.K, 2002; Gilbert S. Banker;     
Lee V.H., Robinson J.R).    
Advantages of controlled drug delivery systems  
 Improved patient convenience and compliance  
 Reduction in fluctuation in steady state levels. 
 Increased safety margin of high potency drugs. 
 Reduction in dose. 
 Reduction in health care cost.  
 Total dose is low. 
 Reduced GI side effects.  
 Reduced dosing frequency.    
 Better patient acceptance and compliance.  
 Less fluctuation at plasma drug levels.  
 More uniform drug effect  
 Improved efficacy/safety ratio.  
 Dose dumping.   
 Reduced potential for accurate dose adjustment. 
 Need of additional patient education (Jain N.K, 2002; Vyas S.P & Khar, 2002).   
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Disadvantages of controlled drug delivery systems  
 Decreased systemic availability. 
 Poor invitro-in vivo correlations. 
 Chances of dose dumping. 
 Dose withdrawal is not possible. 
 Higher cost of formulation. 
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CHAPTER II 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM-REVIEW 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM: 
Oral administration is the most convenient and preferred means of any drug 
delivery to the systematic circulation. Oral controlled release drug delivery have recently 
been of increasing interest in pharmaceutical field to achieve improved therapeutic 
advantages, such as ease of dosing administration, patient compliance and flexibility in 
formulation. Drugs that are easily absorbed from gastrointestinal tract (GIT) and have 
short half-lives are eliminated quickly from the systemic circulation. Frequent dosing of 
these drugs is required to achieve suitable therapeutic activity (Amit Kumar Nayak et al., 
2010).  
To avoid this limitation, the development of oral sustained-controlled release 
formulations is an attempt to release the drug slowly into the gastrointestinal tract (GIT) 
and maintain an effective drug concentration in the systemic circulation for a long time. 
After oral administration, such a drug delivery would be retained in the stomach and 
release the drug in a controlled manner, so that the drug could be supplied continuously to 
its absorption sites in the gastrointestinal tract (GIT).  
These drug delivery systems suffer from mainly two adversities: the short gastric 
retention time (GRT) and unpredictable short gastric emptying time (GET), which can 
result in incomplete drug release from the dosage form in the absorption zone (stomach or 
upper part of small intestine) leading to diminished efficacy of administered dose. To 
formulate a site-specific orally administered controlled release dosage form, it is desirable 
to achieve a prolong gastric residence time by the drug delivery. Prolonged gastric 
retention improves bioavailability, increases the duration of drug release, reduces drug 
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waste, and improves the drug solubility that are less soluble in a high pH environment. 
Also prolonged gastric retention time (GRT) in the stomach could be advantageous for 
local action in the upper part of the small intestine (e.g. treatment of peptic ulcer, etc) 
(Amit Kumar Nayak et al., 2010). 
Gastro retentive drug delivery is an approach to prolong gastric residence time, 
thereby targeting site-specific drug release in the upper gastrointestinal tract (GIT) for 
local or systemic effects. Gastro retentive dosage forms can remain in the gastric region 
for long periods and hence significantly prolong the gastric retention time (GRT) of 
drugs. Over the last few decades, several gastro retentive drug delivery approaches being 
designed and developed, including: High density (sinking) systems that is retained in the 
bottom of the stomach, Low density (floating) systems that causes buoyancy in gastric 
fluid, mucoadhesive systems that causes bioadhesion to stomach mucosa, unfoldable, 
extendible, or swellable systems which limits emptying of the dosage forms through the 
pyloric sphincter of stomach, super porous hydrogel systems, magnetic systems  etc. The 
current review deals with various gastro retentive approaches that have recently become 
leading methodologies in the field of site-specific orally administered controlled release 
drug delivery systems (Amit Kumar Nayak et al., 2010). 
 
BIOLOGICAL ASPECTS OF GRDFs 
Anatomy of the gastrointestinal tract: 
The gastrointestinal tract is divided into three main regions namely: 
 Stomach.  
 Small intestine (Duodenum, Jejunum and Iieum).             
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motions. In the empty state, the stomach is contracted and its mucosa and sub mucosa are 
thrown up into distinct folds called rugae (Natasha Sharma et al., 2011). 
The stomach is anatomically divided into three parts,  
 Fundus  
 Body  
 Antrum (or pylorus).  
 
 
Figure 2: Physiology of stomach 
There are images to four major types of secretary epithelial cells that cover the 
surface of the stomach and extend down into gastric pits and glands 
 Mucous cells: secrete alkaline mucus that protects the epithelium against shear 
stress and acid. 
 Parietal cells: secrete hydrochloric acid. 
 Chief cells: secrete pepsin, a proteolytic enzyme. 
 G cells: secrete the hormone gastrin. 
CHAPTER II               GASTRORETENTIVE DRUG DELIVERY SYSTEM  
 
FLOATING DRUG DELIVERY SYSTEM Page 27 
 
The contraction of gastric smooth muscle serves two basic functions: 
 Ingested food is crushed, ground, mixed and liquefying to form Chyme. 
 Chyme is forced through the pyloric canal into the small intestine, a process called 
gastric emptying. 
The proximal stomach, made up of the fundus and body regions, serves as a 
reservoir for ingested materials while the distal region (antrum) is the major site of 
mixing motions, acting as a pump to accomplish gastric emptying. Gastric emptying 
occurs during fasting as well as fed states. The pattern of motility is however distinct in 
the 2 states. During the fasting state an interdigestive series of electrical events take place, 
which cycle both through stomach and intestine every 2 to 3 hours. This is called the 
interdigestive myloelectric cycle or migrating myloelectric cycle (MMC), which is further 
divided into following 4 phases as described by Wilson and Washington (Neha Narang et 
al., 2011). 
 
 
Figure 3: Schematic representation of Interdigestive Motility 
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Table1: Four phases in migrating myoelectric complex (MMC)           
(Shweta Arora et al., 2005) 
 
Phase I 
It is a quiescent period lasting from 30 to 60 minutes with no 
contractions. 
Phase II 
It consists of intermittent contractions that gradually increase in 
intensity as the phase progresses, and it lasts about 20 to 40 minutes. 
Gastric discharge of fluid and very small particles begins later in this 
phase. 
Phase III 
This is a short period of intense distal and proximal gastric 
contractions (4–5 contractions per minute) lasting about 10 to 20 
minutes; these contractions, also known as ‘‘House-keeper wave,’’ 
sweep gastric contents down the small Intestine. 
Phase IV 
This is a short transitory period of about 0 to 5 minutes, and the 
contractions dissipate between the last part of phase III and quiescence 
of phase I. 
 
Need for gastroretention  
 Drugs that are absorbed from the proximal part of the gastrointestinal tract (GIT). 
 Drugs that are less soluble or that degrade at the alkaline pH. 
 Drugs that are absorbed due to variable gastric emptying time. 
 Local or sustained drug delivery to the stomach and proximal small intestine to 
treat certain conditions. 
 Treatment of peptic ulcers caused by H.Pylori infections (Amit Kumar Nayak et 
al., 2010).  
POTENTIAL DRUG CANDIDATES FOR GASTRORETENTIVE DRUG 
DELIVERY SYSTEMS 
 Drugs those are locally active in the stomach. 
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 Drugs that have narrow absorption window in gastrointestinal tract (GIT) 
 Drugs those are unstable in the intestinal or colonic environment  
 Drugs that disturb normal colonic microbes  
 Drugs that exhibit low solubility at high pH values (Amit Kumar Nayak et al., 
2010) 
 
DRUGS THOSE ARE UNSUITABLE FOR GASTRORETENTIVE DRUG 
DELIVERY SYSTEMS 
 
 Drugs that have very limited acid solubility e.g. Phenytoin etc. 
 Drugs that suffer instability in the gastric environment e.g. Erythromycin etc. 
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc (Amit Kumar Nayak et al., 2010). 
Formulation aspects for GRDDS  
 It must be effective retention in the stomach to suit for the clinical demand.  
 It must be convenient for intake to facilitate patient compliance.  
 It must have sufficient drug loading capacity and control drug release profile.  
 It must have full degradation and evacuation of the system once the drug release is 
over.  
 It should not have effect on gastric motility including emptying pattern.  
 It should not have other local adverse effects (Vinod K.R. et al., 2010) 
Factors affecting gastric retention
 
The gastric retention time (GRT) of dosage form is controlled by several factors 
that affect their efficacy as a gastro retentive system (Vinod K.R. et al., 2010; Vaishali 
Sharma    et al., 2011). 
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1. Density: Gastric retention time (GRT) is a function of buoyancy of dosage form 
that is dependent on the density.  
2. Size: Dosage form units with a diameter of more than 7.5 mm are reported to have 
an increased GRT compared with those with a diameter of 9.9 mm.  
3. Shape: Tetrahedron and ring shaped devices with a flexural modulus of 48 and 
22.5 kilo pounds per square inch (KSI) are reported to have better GRT 90% to 
100% retention at 24 hours compared with other shapes.  
4. Single or Multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
failure of units, allow co-administration of units with different release profiles or 
containing incompatible substances and permit a larger margin of safety against 
dosage form failure compared with single unit dosage forms. 
5. pH (Hydrogen Ion Concentration) –  The mean pH (+ S.D.) along the G.I. Tract 
in normal subjects are given by: 
Region Mean pH 
Stomach 1.8 + 0.6 
Proximal Small Intestine 6.6 + 0.5 
Mid Small Intestine 7.4 + 0.4 
Distal Small Intestine 7.5 + 0.5 
Right Colon 6.3 + 0.6 
Mid Colon 6.6 + 0.8 
Left Colon 7.1 + 0.7 
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The pH of the stomach in fasting state is ~1.5 to 2.0 and in fed state is 2.0 to 6.0. 
A large volume of water administered with an oral dosage form raises the pH of stomach 
contents to 6.0 to 9.0. Stomach doesn’t get time to produce sufficient acid when the liquid 
empties the stomach.  
The various pH of the gastro intestinal tract is shown in Figure 4. 
 
Figure 4:  pH of Gastro Intestinal Tract 
6. Fed or unfed state: Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2hrs. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides with that 
of the MMC, the GRT of the unit can be expected to be very short. However, in 
the fed state, MMC is delayed and GRT is considerably longer.  
7. Nature of meal: Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release.  
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8. Caloric content: GRT can be increased by 4 to 10 hours with a meal that is high 
in proteins and fats.  
9. Frequency of feed: The GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC.  
10. Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with 
their age and race matched female counterparts (4.6±1.2 hours), regardless of the 
weight, height and body surface.  
11. Age: Elderly people, especially those over 70, have a significantly longer GRT.  
12. Posture: GRT can vary between supine and upright ambulatory states of the 
patient.  
13. Concomitant drug administration: Anticholinergics like atropine, 
propantheline, opiates like codeine and prokinetic agents like Metoclopramide and 
Cisapride, can affect floating time.        
14. Biological factors: Diabetes and Crohn’s disease etc. 
Approaches to Gastric retention 
Various approaches have been pursued to increase the retention of an oral dosage 
form in the stomach. These systems include (Vinod K.R. et al., 2010; Vaishali Sharma et 
al., 2011), 
 
 
Figure 5: In vivo picturisation of various gastro retentive formulations 
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Figure 6: Schematic representation of various Gastro retentive formulations            
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Figure 7: APPROACHES TO GASTRIC RETENTION  
1. High density (sinking) system or non- floating drug delivery 
system: 
This approach involves formulation of dosage forms with the density that must 
exceed density of normal stomach content (~ 1.004 gm/cm
3
). These formulations are 
prepared by coating drug on a heavy core or mixed with inert materials such as iron 
powder, barium sulphate, zinc oxide and titanium oxide etc. The materials increase 
density by up to 1.5- 2.4 gm/cm
3
. A density close to 2.5 gm/cm
3
 seems necessary for 
significant prolongation of gastric residence time. But, effectiveness of this system in 
human beings was not observed and no system has been marketed (Amit Kumar Nayak et 
al., 2010). 
 
Figure 8: High density systems 
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2. Floating system or Low density system: 
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids 
and thus remain buoyant in the stomach, (Figure 9), for a prolonged period of time, 
without affecting the gastric emptying rate and the drug is released slowly at a 
desired rate from the system, results in an increase in the gastric residence time and a 
better control of fluctuations in the plasma drug concentrations and after complete release 
of the drug, the residual system is emptied from the stomach (Neha Narang et al., 2011). 
 
Figure 9: Low density systems (Floating system) 
3. Expandable, unfoldable and swellable systems: 
These systems are also called as “Plug type system”, since they exhibit tendency 
to remain logged in the pyloric sphincters. These polymeric matrices remain in the 
gastric cavity for several hours even in fed state. By selection of polymer with the 
proper molecular weight and swelling properties controlled and sustained drug release 
can be achieved. Upon coming in contact with gastric fluid, the polymer imbibes 
water and swells. 
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Figure 10: Swellable tablet in stomach 
A dosage form in the stomach will withstand gastric transit if it bigger than 
pyloric sphincter. However, the dosage form must be small enough to be swallowed, and 
must not cause gastric obstruction either singly or by accumulation. Thus, their 
configurations are required to develop an expandable system to prolong gastric retention 
time (GRT), 
 A small configuration for oral intake, 
 An expanded gastro retentive form, and 
 A final small form enabling evacuation following drug release from the device. 
Thus, gastroretentivity is improved by the combination of substantial dimension with 
high rigidity of dosage form to withstand peristalsis and mechanical contractility of the 
stomach.  
Unfoldable and Swellable systems have been investigated and recently tried to 
develop an effective gastro retentive drug delivery. Unfoldable systems are made of 
biodegradable polymers. They are available in different geometric forms like tetrahedron, 
ring or planner membrane (4 - label disc or 4 - limbed cross form) of bio erodible 
polymer compressed within a capsule which extends in the stomach. Swellable systems 
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are also retained in the gastro intestinal tract (GIT) due to their mechanical properties. 
The swelling is usually results from osmotic absorption of water and the dosage form is 
small enough to be swallowed by the gastric fluid (Amit Kumar Nayak et al., 2010). 
 
Figure 11: Drug release from swellable systems 
Expandable systems have some drawbacks like problematical storage of much 
easily hydrolysable, biodegradable polymers relatively short-lived mechanical shape 
memory for the unfolding system most difficult to industrialize and not cost effective. 
Again, permanent retention of rigid, large single-unit expandable drug delivery dosage 
forms may cause brief obstruction, intestinal adhesion and gastropathy. 
4. Bioadhesive or Mucoadhesive drug delivery systems: 
 
Bioadhesive drug delivery systems are used as materials commonly used for 
bioadhesion are poly acrylic acid, chitosan, cholestyramine, sodium alginate, 
hydroxypropyl methylcellulose (HPMC), sucralfate, tragacanth, dextrin, polyethylene 
glycol (PEG) and polylactic acids etc. Even though some of these polymers are effective 
at producing bioadhesive, it is very difficult to maintain it effectively because of the rapid 
turnover of mucus in the gastrointestinal tract (GIT) (Amit Kumar Nayak et al., 2010; 
Sunil Kumar et al., 2012). 
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1. Hydration-mediated adhesion: 
Certain hydrophilic polymers tend to imbibe large amount of water and become 
sticky, thereby acquiring bio adhesive properties (Anand S. Surana et al., 2010). 
2. Bonding-mediated adhesion: 
The adhesion of polymers to a mucus/epithelial cell surface involves various 
bonding mechanisms, including physical-mechanical bonding and chemical bonding.               
Physical-mechanical bonds can result from the insertion of the adhesive material into the 
folds or crevices of the mucosa. Chemical bonds may be either covalent (primary) 
or ionic (secondary) in nature. Secondary chemical bonds consist of dispersive 
interactions (i.e., Vander Waals interactions) and stronger specific interactions such as 
hydrogen bonds. The hydrophilic functional groups responsible for forming hydrogen 
bonds are the hydroxyl and carboxylic groups (Anand S. Surana et al., 2010). 
3. Receptor-mediated adhesion: 
Certain polymers bind to specific receptor sites on the cell surfaces, thereby 
enhancing the gastric retention of dosage forms.  
Various investigators have proposed different mucin-polymer interactions, such 
as: 
 Wetting and swelling of the polymer to permit intimate contact with the biological 
tissue.  
 Interpenetration of bio adhesive polymer chains and entanglement of polymer and 
mucin chains.  
 Formation of weak chemical bonds.  
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 Sufficient polymer mobility to allow spreading.  
 Water transport followed by mucosal dehydration.  
The bioadhesive coated system when comes in contact with the mucus layer, various   
non-specific (Vander Waals, hydrogen bonding and/or hydrophobic interactions) or 
specific interactions occurs between the complimentary structures and these interactions 
last only until the turnover process of mucin and the drug delivery system should release 
its drug contents during this limited adhesion time, in order for a bio adhesive system to 
be successful (Anand S. Surana et al., 2010). 
5. Magnetic Systems 
This approach to enhance the gastric retention time (GRT) is based on the simple 
principle that the dosage form contains a small internal magnet, and a magnet placed on 
the abdomen over the position of the stomach. Although magnetic system seems to work, 
the external magnet must be positioned with a degree of precision that might compromise 
patient compliance (Anand S. Surana et al., 2010; Sunil Kumar et al., 2012).   
6. Super porous hydrogel systems 
These swellable systems differ sufficiently from the conventional types to warrant 
separate classification. In this approach to improve gastric retention time (GRT) super 
porous hydrogels of average pore size >100 micro meter, swell to equilibrium size within 
a minute due to rapid water uptake by capillary wetting through numerous interconnected 
open pores . They swell to a large size (swelling ratio: 100 or more) and are intended to 
have sufficient mechanical strength to withstand pressure by gastric contraction. This is 
advised by co-formulation of hydrophilic particulate material (Sunil Kumar et al., 2012). 
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Figure 12: Typical swelling and mechanical properties of the SPH generations. 
 
7. Raft-forming systems: 
 
These systems,  contain gel-forming solution (e.g. sodium alginate solution containing 
carbonates or bicarbonates), which on contact with the gastric contents, swells and forms 
a viscous cohesive gel containing entrapped CO2 bubbles, releases drug slowly in 
stomach by forming the raft layer on the top of gastric fluid. These formulations contain 
antacids such as calcium carbonate or aluminium hydroxide to reduce gastric acidity 
(Neha Narang et al., 2011; Shah S.H et al., 2009).  
 
Figure 13: Schematic illustration of the barrier formed by a raft-forming system 
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CHAPTER III 
FLOATING DRUG DELIVERY SYSTEM-REVIEW 
The concept of FDDS was first described in the literature as early as 1968, when 
Davis (1968) disclosed a method to overcome the difficulty experienced by some persons 
of gagging or choking after swallowing medicinal pills. The author suggested that such 
difficulty could be overcome by providing pill having a density of less than 1.0g/cm
3
, so 
that pill will float on water surface. Since then several approaches have been used to 
develop an ideal floating drug delivery system. 
MECHANISM OF FLOATING DRUG DELIVERY SYSTEM  
Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids 
and so remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents (Figure 1), 
the drug is released slowly at the desired rate from the system.  After release of drug, the 
residual system is emptied from the stomach. This results in an increased GRT and a 
better control of the fluctuations in plasma drug concentration (Praveen Nasa et al., 
2010).  
However, besides a minimal gastric content needed to allow the proper 
achievement of the buoyancy retention principle, a minimal level of floating force (F) is 
also required to keep the dosage form reliably buoyant on the surface of the meal.  
The floating force kinetics is measured using a novel apparatus by determining the 
resultant weight (RW). The RW apparatus operates by measuring continuously the force 
equivalent to F (as a function of time) that is required to maintain the submerged object.  
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The object floats better if RW is on the higher positive side. This apparatus helps 
in optimising FDDS with respect to stability and durability of floating forces produced in 
order to prevent the drawbacks of unforeseeable intragastric buoyancy capability 
variations (Shah et al., 2009).  
RW or F = F buoyancy - F gravity 
= (Df - Ds) gV, 
Where, 
 RW = total vertical force,  
 Df = fluid density,  
 Ds = object density,  
 V = volume and        
 g = acceleration due to gravity. 
In case of gas generating systems, carbon dioxide is released, causing the beads to 
float in the stomach. And in case of non-effervescent systems, the air trapped by the 
swollen polymer confers buoyancy to these dosage forms. 
 
Figure 1:  Mechanism of Floating systems 
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CLASSFICATION 
Based on the mechanism of buoyancy, two different technologies have been used 
in development of floating drug delivery systems (Praveen Nasa et al., 2010). These 
include: 
a) Non- Effervescent system. 
b) Effervescent system. 
 NON-EFFERVESCENT SYSTEM 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in 
noneffervescent.  FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as 
chitosan and carbopol (Amit Kumar Nayak et al., 2010). 
The various types of this system are as 
1. Single layer floating tablets. 
2. Bilayer floating tablets. 
3. Alginate beads. 
4. Hollow microspheres. 
Single layer floating tablets 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity. 
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They are formulated by intimate mixing of drug with low-density enteric materials such 
as HPMC (Vinod K.R et al., 2010). 
Bilayer floating tablets 
A bilayer tablet contain two layer one immediate release layer which release 
initial dose from system while the another sustained release layer absorbs gastric fluid, 
forming an impermeable colloidal gel barrier on its surface, and maintain a bulk density 
of less than unity and thereby it remains buoyant in the stomach (Vinod K.R et al., 2010). 
 
Alginate beads 
Multi-unit floating dosage forms were developed from freeze dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
sodium alginate solution into aqueous solution of calcium chloride, causing precipitation 
of calcium alginate leading to formation of porous system, which can maintain a floating 
force for over 12 hours. When compared with solid beads, which gave a short residence 
time of 1 hour, and these floating beads gave a prolonged residence time of more than 5.5 
hours (Shah S.H et al., 2009; Vinod K.R et al., 2010). 
 
Figure 2: Alginate beads 
Hollow microspheres 
Hollow microspheres (microballons), loaded with drug in their outer polymer 
shells were prepared by a novel emulsion-solvent diffusion method (Figure 3). The 
CHAPTER III                            FLOATING DRUG DELIVERY SYSTEM  
 
FLOATING DRUG DELIVERY SYSTEM Page 45 
 
ethanol: dichloromethane solution of the drug and an enteric acrylic polymer was poured 
into an agitated aqueous solution of PVA that was thermally controlled at 40
0
C. The gas 
phase generated in dispersed polymer droplet by evaporation of dichloromethane formed 
an internal cavity in microsphere of polymer with drug. The microballons floated 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in vitro (Vinod K.R et al., 2010).  
 
 
Figure 3: Formulation of floating hollow microsphere or microballoon 
 
EFFERVESCENT SYSTEM 
A drug delivery system can be made to float in the stomach by incorporating a 
floating chamber, which may be filled with vacuum, air or inert gas. The gas in floating 
chamber can be introduced either by volatilization of an organic solvent or by 
effervescent reaction between organic acids and bicarbonate salts (Shayeda et al., 2009). 
These effervescent systems further classified into two types: 
1)      Volatile liquid or vacuum containing systems. 
2)      Gas generating systems. 
 
CHAPTER III                            FLOATING DRUG DELIVERY SYSTEM  
 
FLOATING DRUG DELIVERY SYSTEM Page 46 
 
Volatile liquid or vacuum containing systems 
    (a) Intragastric floating gastrointestinal drug delivery system 
This system floats in the stomach because of floatation chamber, which is vacuum 
or filled with a harmless gas or air, while the drug reservoir is encapsulated by a 
microporous compartment (Vinod K.R et al., 2010). 
 
Figure 4: Intragastric floating gastrointestinal drug delivery device 
 (b) Inflatable gastrointestinal delivery systems   
These systems are incorporated with an inflatable chamber, which contains liquid 
ether that gasifies at body temperature to inflate the chamber in the stomach. These 
systems are fabricated by loading the inflatable chamber with a drug reservoir, which can 
be a drug, impregnated polymeric matrix, then encapsulated in a gelatin capsule, (Figure 
5). After oral administration, the capsule dissolves to release the drug reservoir together 
with the inflatable chamber. The inflatable chamber automatically inflates and retains the 
drug reservoir compartment in the stomach. The drug is released continuously from the 
reservoir into gastric fluid (Vinod K.R et al., 2010; Sunil Kumar et al., 2012). 
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Figure 5:  Inflatable gastrointestinal delivery system 
(c) Intragastric osmotically controlled drug delivery system 
This system is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a biodegradable capsule, (Figure 6). On contact with 
the gastric contents in the stomach, the capsule disintegrates quickly to release the 
intragastirc osmotically controlled drug delivery device. The inflatable support inside 
forms a hollow polymeric bag which contains a liquid that gasifies at body temperature to 
inflate the bag and it is deformable. The osmotic pressure controlled drug delivery device 
consists of two components, osmotically active compartment and a drug reservoir 
compartment. The drug reservoir compartment is enclosed by a pressure responsive 
collapsible bag, which is impermeable to liquid and vapour and has a drug delivery 
orifice. The osmotically active compartment contains an osmotically active salt and is 
enclosed within a semi-permeable housing. In the stomach, the osmotically active salt 
present in the osmotically active compartment is dissolved by absorbing the water 
continuously present in the GI fluid through the semi-permeable membrane. An osmotic 
pressure is thus created which acts on the collapsible bag and in turn forces the drug 
reservoir compartment to reduce its volume and activate the drug reservoir compartment 
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to reduce its volume and activate the drug release of a drug solution formulation through 
the delivery orifice. The floating support is also made to contain a bioerodible plug that 
erodes after a predetermined time to deflate the support. The deflated drug delivery 
system is then emptied from the stomach (Amit Kumar et al., 2011; Vinod K.R et al., 
2010). 
 
Figure 6: Intragastric osmotically controlled drug delivery system 
GAS GENERATING SYSTEM 
These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets entrapped 
in the gellified hydrocolloid layer of the systems thus decreasing its specific gravity and 
making it to float over chyme (Sunil Kumar et al., 2012). 
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Figure 7:  Drug release from effervescent (gas generating) systems 
 
A) Tablets:
 
1. Intragastric single layer floating tablets or Hydrodynamically Balanced System     
(HBS)   
These formulations have bulk density lower than gastric fluids and thus float in 
the stomach that increases the gastric emptying rate for a prolonged period, (Figure 8). 
These are formulated by intimately mixing the gas (CO2) generating agents and the drug 
within the matrix tablet.  The drug is released slowly at a desired rate from the floating 
system and the residual system is emptied from the stomach after the complete release of 
the drug.  This leads to an increase in the gastric residence time (GRT) and a better                           
control over fluctuations in plasma drug concentration (Vinod K.R et al., 2010;                
Sunil Kumar et al., 2012). 
 
Figure 8: Intragastric single layer floating tablet 
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2. Intragastric bilayer floating tablets  
These are also compressed tablets, containing two layers (Figure 9): 
 Immediate release layer 
 Sustained release layer.   
 
Figure 9: Intragastric bilayer floating tablet 
B) Floating capsules 
These floating capsules are formulated by filling with a mixture of sodium 
alginate and sodium bicarbonate. The systems float as a result of the generation of CO2 
that was trapped in the hydrating gel network on exposure to an acidic environment 
(Vinod K.R et al., 2010).  
C) Multiple unit type floating pills 
  These multiple unit type floating pills are sustained release pills, known as 
‘seeds’, which are surrounded by two layers (Figure 10). The outer layer is of swellable 
membrane layer while the inner layer consists of effervescent agents. This system sinks at 
once and then it forms swollen pills like balloons which float as they have lower density, 
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when it is immersed in the dissolution medium at body temperature. The lower density is 
due to generation and entrapment of CO2 within the system (Amit Kumar et al., 2011;               
Vinod K.R et al., 2010). 
 
Figure: 10 (a) A multiple-unit oral floating dosage system. (b) Stages of floating 
mechanism: (A) penetration of water; (B) generation of CO2 and floating; (C) 
dissolution of drug. Key: (a) conventional SR pills; (b) effervescent layer; (c) 
swellable layer; (d) expanded swellable membrane layer; (e) surface of water in the 
beaker (37
0
C). 
D) Floating system with Ion-Exchange resins 
Floating system using bicarbonate loaded ion exchange resin was made by mixing 
the beads with 1M sodium bicarbonate solution, and then the semi-permeable membrane 
is used to surround the loaded beads to avoid sudden loss of CO2. On contact with gastric 
contents an exchange of bicarbonate and chloride ions takes place that results in 
generation of CO2 that carries beads towards the top of gastric contents and producing a 
floating layer of resin beads (Amit Kumar et al., 2011).  
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Advantages of Floating drug delivery system 
1. The FDDS are advantageous for drugs absorbed through the stomach                 
(e.g. ferrous salts) and for drugs meant for local action in the stomach and treatment of 
peptic ulcer disease (e.g. Antacids). 
2. Acidic substances like aspirin cause irritation on the stomach wall when come 
in contact with it. Hence FDDS may be useful for the administration of aspirin and other 
similar drugs. 
3. Administration of prolongs release floating dosage forms, tablet or capsules, 
will result in dissolution of the drug in the gastric fluid. They dissolve in the gastric fluid 
would be available for absorption in the small intestine after emptying of the stomach 
contents. 
4. Drug will be fully absorbed from floating dosage forms if it remains in the 
solution form even at the alkaline pH of the intestine (Natasha Sharma et al., 2011) 
5. FODDS provides advantages such as the delivery of drugs with narrow 
absorption windows in the small intestinal region (Vaishali Sharma et al., 2011) 
 
Disadvantages of Floating drug delivery system 
 
1. These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently coat, water. 
2. Drugs that are significantly absorbed through out gastrointestinal tract, which 
undergo significant first pass metabolism, are only desirable candidate (Natasha Sharma        
et al., 2011) 
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3. Drugs that may irritate the stomach lining or are unstable in its acidic 
environment should not be formulated in gastro retentive systems (Vaishali Sharma et al., 
2011) 
MARKETED PRODUCTS OF FDDS (Natasha Sharma et al., 2011; Shweta Arora et 
al., 2005) 
 
S.NO 
 
BRAND 
NAME 
 
DRUG (DOSE) 
 
COMPANY 
 
REMARKS 
1. 
Modapar® 
Levodopa (100mg) 
Benserazide (25mg) 
Roche 
Products, 
USA. 
Floating CR 
capsule 
2. 
Valrelease® Diazepam (15mg) 
Hoffmann-
LaRoche USA 
Floating 
capsule 
3. 
Liquid 
gavison® 
Al hydrodxide (95mg),     
Mg carbonate  (358 
mg) 
Glaxo Smith 
Kline, India 
Effervescent 
floating liquid 
alginate 
preparation 
4. 
Topalkan® Al-Mg antacid 
Pierre Fabre 
Drug, France 
Floating liquid 
alginate 
preparation 
5. 
Conviron® Ferrous sulphate Ranbaxy, India 
Colloidal gel 
forming FDDS 
6. 
Cifran OD® Ciprofloxacin  (1 gm) Ranbaxy, India 
Gas-generating 
floating tablet 
7. 
Cytotec® 
Misoprostal (100 
mcg/200 mcg) 
Pharmacia, 
USA 
Bilayer floating 
capsule 
8. 
Oflin OD® Ofloxacin    (400 mg) Ranbaxy, India 
Gas generating 
floating tablet 
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POLYMERS AND OTHER INGREDIENTS USED IN THE FORMULATION OF 
FLOATING DRUG DELIVERY SYSTEM 
Category Materials 
Polymers 
HPMC K4 M, Calcium alginate, Eudragit S100, Eudragit RL, 
Propylene foam, Eudragit RS, ethyl cellulose, polymethyl 
meth acrylate, Methocel K4M, Polyethylene oxide,              
β Cyclodextrin, HPMC 4000, HPMC 100, CMC, Polyethylene 
glycol, polycarbonate, PVA, Polycarbonate, Sodium alginate, 
HPC-L, CP 934P, HPC, Eudragit S, HPMC, Metolose S.M. 
100, PVP, HPC-H, HPC-M, HPMC K15, Polyox, HPMC K4, 
Acrylic polymer, E4 M and Carbopol 
Inert fatty materials (5%-75%) 
Edible, inert fatty materials having a specific gravity of less 
than one can be used to decrease the hydrophilic property of 
formulation and hence increase buoyancy. E.g. Beeswax, fatty 
acids, long chain fatty alcohols, Gelucires® 39/01 and 43/01. 
Effervescent agents 
Sodium bicarbonate, citric acid, tartaric acid, Di-SGC          
(Di-Sodium Glycine Carbonate), CG (Citroglycine) 
Release rate accelerants (5%-60%) lactose, mannitol 
Release rate retardants (5%-60%) Dicalcium phosphate, talc, magnesium stearate 
Buoyancy increasing agents 
(upto80%) 
Ethyl cellulose 
Low density material 
 
Polypropylene foam powder (Accurel MP 1000®) 
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EVALUATION OF FLOATING DRUG DELIVERY SYSTEMS 
(1) PRELIMINARY EVALUATION: 
a) Buoyancy Lag Time 
 It is determined in order to assess the time taken by the dosage form to float on the 
top of the dissolution medium, after it is placed in the medium. These parameters 
can be measured as a part of the dissolution test. 
b) Floating Time 
 Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid 
maintained at 37
0
C. The time for which the dosage form continuously floats on 
the dissolution media is termed as floating time. 
(2) IN VITRO DISSOLUTION TESTS 
 In vitro dissolution test is generally done by using USP apparatus with paddle and 
GRDDS is placed normally as for other conventional tablets. But sometimes as 
the vessel is large and paddles are at bottom, there is much lesser paddle force acts 
on floating dosage form which generally floats on surface. As floating dosage 
form not rotates may not give proper result and also not reproducible results. 
Similar problem occur with swellable dosage form, as they are hydrogel may stick 
to surface of vessel or paddle and gives irreproducible results. In order to prevent 
such problems, various types of modification in dissolution assembly made are as 
follows. 
 To prevent sticking at vessel or paddle and to improve movement of dosage form, 
method suggested is to keep paddle at surface and not too deep inside dissolution 
medium. 
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 Floating unit can be made fully submerged, by attaching some small, loose, non 
reacting material, such as few turns of wire helix, around dosage form. However 
this method can inhibit three dimensional swelling of some dosage forms and also 
affects drug release. 
 Other modification is to make floating unit fully submerged under ring or mesh 
assembly and paddle is just over ring that gives better force for movement of unit. 
 Other method suggests placing dosage form between 2 ring/meshes. 
 In previous methods unit have very small area, which can inhibit 3D swelling of 
swellable units, another method suggest the change in dissolution vessel that is 
indented at some above place from bottom and mesh is place on indented 
protrusions, this gives more area for dosage form. 
 Inspite of the various modifications done to get the reproducible results, none of 
them showed co-relation with the in vivo conditions. So a novel dissolution test 
apparatus with modification of Rossett-Rice test Apparatus was proposed.  
(3) IN VIVO EVALUATION 
a) Radiology 
 X-ray is widely used for examination of internal body systems. Barium Sulphate 
is widely used Radio Opaque Marker. So, BaSO4 is incorporated inside dosage 
form and X-ray images are taken at various intervals to view GR. 
b) Scintigraphy 
 Similar to X-ray, emitting materials are incorporated into dosage form and then 
images are taken by scintigraphy. Widely used emitting material is 99Tc. 
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c) Gastroscopy 
 Gastroscopy is per oral endoscopy used with fibre optics or video systems. 
Gastroscopy is used to inspect visually the effect of prolongation in stomach. It 
can also give the detailed evaluation of GRDDS. 
d) Magnetic Marker Monitoring 
 In this technique, dosage form is magnetically marked with incorporating iron 
powder inside, and images can be taken by very sensitive bio-magnetic 
measurement equipment. Advantage of this method is that it is radiation less and 
so not hazardous. 
e) Ultrasonography 
 Used sometimes, not used generally because it is not traceable at intestine         
(Shweta Arora et al., 2005; Gopalakrishnan S et al., 2011). 
 
APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEM 
Sustained drug delivery: 
   Hydrodynamically Balanced System (HBS) type are dosage forms which have 
bulk density less than one, relatively large in size and did not easily pass through pylorus,                     
releases the drug over a prolonged period of time by retaining in the stomach for 
several hours  and by increasing the gastric residence time (Kwon H. Kim et al., 2000).  
 Site specific drug delivery: 
Floating drug delivery systems are particularly useful for drugs having specific 
absorption from stomach or proximal part of the small intestine e.g. riboflavin, 
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furosemide etc. The absorption of captopril has been found to be site specific, 
stomach being the major site followed by duodenum (Amit Kumar et al., 2011).  
 Absorption enhancement: 
Drugs that have  poor bioavailability, because of their absorption  is  restricted  to 
upper  GIT are potential candidates  to be formulated as  floating drug delivery systems, 
thereby improving  their  absolute  bioavailability.        
Minimized adverse activity at the colon  
Retention of the drug at the stomach (HBS system), minimizes the amount of drug 
that reaches the colon, that prevents the undesirable activities of the drug in colon. This 
Pharmacodynamic aspect provides the rationale for GRDF formulation for 
betalactam antibiotics that are absorbed only from the small intestine, and whose presence 
in the colon leads to the development of microorganism’s resistance. 
Reduction in plasma fluctuations: 
Patients with advanced Parkinson’s disease, experienced pronounced fluctuations 
in symptoms while treatment with standard L-dopa.  A HBS dosage form provided a 
better control of motor fluctuations although its bioavailability was reduced by 50-60% of 
the standard formulation. 
Peptic ulcer treatment: 
H. Pylori, causative bacterium for peptic ulcers and chronic gastritis. Patients 
require high concentration of drug, to be maintained at the site of infection that is within 
the gastric mucosa. The floating dosage form due to its floating ability was retained in 
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stomach and maintained high concentration of drug in the stomach. A sustained liquid 
preparation of Ampicillin, using sodium alginate was developed that spreads out and 
adheres to gastric mucosal surfaces and releases the drug continuously. 
Suitable for poorly absorbed drugs. 
  Floating drug delivery systems are particularly useful for drugs which are poorly 
soluble or unstable in intestinal fluids and acid stable drugs and for those which undergo 
abrupt changes in their pH-dependent solubility due to pathophysiological conditions of 
GIT, food and age, e.g. floating system for furosemide lead to potential treatment of 
Parkinson’s disease. Approximate 30% drug was absorbed after oral administration 
(Shweta Arora et al., 2005). 
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0, formulate floating tablets of famotidine w
anulation technique.  In the present study th
er gastric cytoprotection when compared w
ue to its extended duration of release and ac
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ms to inhibit the 
 develop floating 
ity of the drug by 
ation of sodium 
stric fluid when 
trapped inside the 
ng in lowering of 
livery system of 
8 ATO by using 
PMC K100 LV.  
lution test. 
livery system by 
ing cacl2 as cross 
 of drug delivery 
oavailability and 
 stomach. 
as prepared with 
e floating tablets 
ith conventional 
tion. 
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 Margret Chandira R et a
using an effervescent appro
tablet formulations were ev
vitro drug release, weight 
tablets of itopride hydrochlo
and 40mg of carbopol prov
bioavailability. 
Lingaraj S. Danki et al., 
systems of alfuzosin Hcl by
that alfuzosin Hcl for increa
benign prostatic hyperplasi
better control of fluctuation
Mandal S et al., 2010, 
tablets of tizanidine Hcl us
were evaluated for Pharmac
of optimized formulations 
product. 
Jadhav Mayur N et al
famotidine was prepared b
effervescent techniques.  I
combination of guar gum a
release pattern as compared
optimum formulation was fo
                                      LITERATURE RE
ERY SYSTEM 
l., 2010, formulates floating tablets of itopr
ach for GRDDS by direct compression met
aluated for physical characterization, swellin
variation.  The results indicated that gas 
ride containing 125mg HPMC K100M, 40m
ides a better option for 24hours release acti
2010, present study in the development of h
 direct compression method using HPMC.  
sing the bioavailability and reliability for hy
a to relieve symptoms of urinary obstructio
s observed with conventional dosage forms.
designed and evaluation of gastro retentive 
ing HPMC K100 by direct compression met
opeial and non-Pharmacopeial tests.  In vitr
were found to be similar to that of comm
., 2010, prepare a gastro retentive drug de
y employing polymers like guar gum and 
t was also concluded that the formulations
nd xanthan gum was more effective in mo
 to the formulations that contains individu
und to be stable during the short term stabili
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ide hydrochloride 
hod. The floating 
g index, assay, in 
powered floating 
g HPMC K15M, 
on and improved 
ydrodynamically 
It was concluded 
pertension and in 
n by allowing a 
 
sustained release 
hod.  The tablets 
o release profiles 
ercial marketed 
livery system of 
xanthan gum by 
 which contained 
difying the drug 
al polymer.  The 
ty testing. 
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Mishra Manoj Kumar et 
were formulated by using
buoyancy to the formulation
be concluded from the pres
ondansetron over a period o
Rajashree Masareddy et 
were prepared by direct co
excipients.  Carbopol con
mechanism and HPMC con
mechanism.  In vitro releas
carbopol with lactose contai
Anilkumar J. Shinde et a
the hydrophilic polymer HP
by 3
2 
factorial design.  The
K100M and citric acid f
cephalexin. 
Nagalakshmi S. et al., 2
Pioglitazone Hcl by non-ef
was identified as that conta
and good controlled release
Rishad R. Jivani et al., 200
of self correcting monolithi
direct compression method.
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al., 2010, gastro retentive floating tablet of
 various low density polymers, which no
s but also reduced floating lag time to a g
ent study that slow, controlled and complet
f 12 hours was obtained from FT10. 
al., 2010, developed single and bilayer tab
mpression technique using HPMC K4M, ca
taining tablets were retained in stomach b
taining tablets were retained in stomach by n
e results indicated that the drug release was 
ning formulations. 
l., 2010, formulate an oral floating tablet of
MC, gas generating agent sodium bicarbona
 results of factorial design indicated that hig
avors preparation of floating sustained 
009, formulated and evaluated floating m
fervescent and effervescent techniques. The
ining HPMC K100 M which exhibited good 
 properties. 
9, present investigation describes the design
c gastro retentive system of baclofen tablets 
  It was concluded that gastro retentive table
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t only imparted 
reat extent.  It may 
e drug release of 
lets of riboflavin 
rbopol and other 
y mucoadhesion 
on-mucoadhesion 
more sustained in 
 cephalexin using 
te and citric acid 
h level of HPMC 
release tablet of 
atrix tablets of 
 best formulation 
floating behavior 
 and development 
were prepared by 
t of baclofen can 
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be prepared via floating and
stomach and thereby increas
Damodharan N et al., 200
granulation technique using
and the tablets were evalu
HPMC and methylcellulose
and were found suitable for 
Ajit Kulkarni et al., 2009,
tablets of atenolol and lovas
for different drugs can be f
in combination) to give con
immediate release of lovast
delivery of two drugs fo
compliance and give better 
Aliasgar Shahiwala et a
pulsatile delivery system fo
mathematical model is foun
coating formulations for p
consistent with the demands
Monica RP Rao et al., 
sulphate by using HPMC 
environment to sodium bic
formulations had a desired 
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 bioadhesion mechanism to increase residen
e absorption. 
9, developed bilayer floating tablets of the
 HPMC, methylcellulose, sodium carboxy
ated.  The formulated tablets employing a
 provide slow release of theophylline over a 
maintenance portion of bilayer floating table
 study was performed to design bilayer regio
tatin.  Bilayer floating tablets having differe
ormulated using HPMC K100M and xantha
trolled release of atenolol and sodium starch 
atin.  Hence this dosage form should be furt
rm, a single dosage form which could 
disease management. 
l., 2009, statistical optimization of ranitid
r chronotherapy of nocturnal acid breakthrou
d to be robust and accurate for optimizatio
rogrammable pulsatile release of ranitidin
 of nocturnal acid breakthrough. 
2009, developed effervescent floating table
and gas generating agent. Stearic acid pr
arbonate, which reduces the BLT in the f
floating time regardless of the viscosity grad
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ce time of drug in 
ophylline by wet 
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 combination of 
period of 9 hours 
ts. 
selective floating 
nt release profiles 
n gum (alone and 
glycollate to give 
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improve patient 
ine Hcl floating 
gh. The proposed 
n of time logged 
e hydrochloride, 
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ovides an acidic 
ed condition. All 
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mechanism of drug release
reported behavior for the ma
Pare A et al., 2008, devel
employing different grade
bicarbonate and citric acid
containing amlodipine besy
and compare with marketed
Arunkumar N et al., 200
system for atrovastatin calc
an alkalizing agent which p
controlled manner for prolo
absorption of the drug can b
Leopoldo Villafuerte Rob
captopril from metolose S
metolose and bicarbonate.
indicative of the release me
dioxide bubbles obstruct the
Manoj N. Gambhire et al
delivery of dilitiazem Hcl 
K100M CR and compritol 
The optimized formulation
floating duration of 24 h
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 was found to be of the anomalous type, wh
trix tablets. 
oped effervescent floating tablets of amlod
s of polymers and effervescent agents 
.  From above the results, the effervesce
late gave slow and complete drug release spr
 product. 
8, present study was aimed at developing
ium with the use of a swellable polymer, rele
roved to be an ideal formulation, as it relea
nged period, the dose can be reduced and po
e avoided. 
les et al., 2008, developed controlled relea
H 4000 SR/Sodium bicarbonate, varying th
  The drug release constant decreases a
chanism increases with increasing polymer 
 diffusion path and decrease the matrix cohe
., 2007, had done a project in effervescent ba
by using gel forming polymer.  Combina
888 ATO has resulted in minimal variation
 gives the best result in terms of the requi
ours, and drug release was in accordanc
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 an oral floating 
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se formulation of 
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nd the exponent 
contents.  Carbon 
rence. 
sed floating drug 
tion of methocel 
 in drug release.  
red lag time and 
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dissolution criteria for exten
formulation. 
Narendra C et al., 2006, 
tartrate by factorial designin
the floating design consi
independent variables were 
dumping, and extend the du
Ziyaur Rahman et al., 200
compression technology us
showed controlled release
and in vivo studies indicated
indicate, a promising poten
conventional dosage form.
Atmaram P Pawar et al.,
release of cefuroxime axetil
for quick onset of action fo
unabsorbed drug entering co
Brijesh et al., 2004, discu
hydrochloride by effervesce
K4M and gas generating so
A systematic study using a 
stearic acid had a significan
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ded release capsule for dilitiazem and match
optimization of bilayer floating tablet conta
g in which polymer HPMC K4M did not si
sts of 8 full factorial designs, dependen
selected.  The dosage form can control the re
ration of action of a drug with prolonged floa
6, developed a bilayer floating tablet of capt
ing various grades of HPMC.  In vitro 
 for 24 hours, followed by the Higuchi diff
 increased GRT.  Thus, the results of the cur
tial of the captopril floating system as an 
 
 2006, designed gastro retentive delivery sy
. Thus, bimodal drug release comprising of i
llowed by controlled release minimizing the
lon was achieved. 
sses the preparation of gastro retentive tab
nt techniques.  The addition of gel forming
dium bicarbonate was essential to achieve 
3
2
 factorial design revealed that the amount 
t effect on t50, t80 and F2. 
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mmediate release 
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 2000, formulated floating matrix tablets 
PH 101 and a gas generating agent. The rele
 enough prolonging drug delivery.  This resu
dence time and higher bioavailability of the 
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AIM
 Cardiovascular dise
Angina pectoris, hyp
require constant mo
that are difficult to t
a major role in the 
antihypertensive dru
used monotherapy o
 
 Valsartan is a poten
inhibits (ACE Inhib
blood pressure and 
drug is prefentially 
drug displays oral bi
 
 An conventional 
biopharmaceutical 
absorption rates wit
system that release 
desired rate.   
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 AND OBJECTIVE OF THE WORK
ases are one of the life threatening diseas
ertension and cardiac failure are the commo
nitoring.  Hypertension is progressive and c
reat effectively in the long term. Antihypert
management of hypertension.  There is a 
gs, indicated for the treatment of hypertensi
r in combination with others. 
t orally active non peptide tetrazole derivativ
itor) angiotensin II receptor type 1 which ca
it’s widely prescribed for treatment of hypert
absorbed in the upper GIT (narrow absorpt
oavailability problems as given in conventio
dosage forms can only partly satisfy 
needs, as it doesn’t take into account 
hin the GIT, therefore there is a need for de
the drug at the right time, at the specific 
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es in the world. 
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ensive drugs play 
wide range of oral 
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e and selectively 
uses reduction in 
ension. Since the 
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nal dosage forms. 
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the site specific 
veloping delivery 
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 To overcome these 
dosage form in the
prolonged and pred
Residence Time (GR
can be retained in th
of drugs that have a
ensuring optimal bio
floating drug delive
system and Superpo
 
 The objective of th
Valsartan are prep
polymers hydrophil
gastric residence tim
the work is to evalua
Invitro drug release,
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problems, different approaches have been p
 stomach. One of the most feasible approac
ictable drug delivery in the GIT is to co
T)    (i.e. Gastro retentive dosage form).  
e stomach and assist in improving the oral s
n absorption window in a particular region
availability.  Gastro retention can be achieve
ry system, High density system, Swelling
rous hydrogels. 
e present study is to develop a floatable 
ared by non-effervescent technique usin
ic and hydrophobic polymers are designe
e and to enhance the drug bioavailability.
te the effect of both hydrophilic and hydrop
 Floating behavior, and In vivo x-ray studies
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The plan of the work involv
STEP-I   
STANDARD CALIBRAT
(a) Preparation of dissolutio
(b) Determination of (Absor
(c) Preparation of standard c
 
STEP-II 
PREFORMULATION (C
(a) Differential scanning
(b) Fourier Transform In
 
STEP-III 
FORMULATION OF VA
 Preparation of Float
of hydrophilic and h
K4M, MC & EC) by
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PLAN OF WORK 
es the following steps: 
ION CURVE OF VALSARTAN 
n medium 
ption Maximum)  λmax of Valsartan by UV s
alibration curve for Valsartan  
OMPATABILITY) STUDIES 
 calorimetric (DSC) studies 
fra Red Spectroscopic (FT-IR) studies  
LSARTAN FLOATING MATRIX TABLE
ing matrix tablets of valsartan using differe
ydrophobic polymers (HPMCK100M, HPM
 using non effervescent technique.  
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STEP-IV 
EVALUATION OF VALS
1. PRECOMPRESSIONA
(a) Angle of Repose 
(b) Bulk Density 
(c) Tapped Density 
(d) Compressibility Index 
(e) Hausner’s Ratio 
(f) Estimation of drug conte
2. POSTCOMPRESSION
TABLET: 
(a) General appearance 
(b) Hardness  
(c) Thickness & Diameter 
(d) Friability test 
(e) Weight variation test 
(f) Estimation of drug conte
3. IN VITRO BUOYANCY
4. SWELLING STUDIES
5. IN VITRO RELEASE S
6. IN VITRO DRUG RELE
 
 
 
                                        PLAN OF W
ERY SYSTEM 
ARTAN FLOATING MATRIX TABLET
L EVALUATION OF POWDER BLEND
nt for powder blend  
AL EVALUATION OF VALSARTA
 
nt for tablets 
 STUDIES 
 
TUDIES 
ASE KINETICS STUDIES 
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STEP-V 
SELECTION OF BEST F
(A) Evaluation of best 
1. Comparison with mar
2. Assay by High perfor
3. Scanning Electron Mi
4. In vivo x-ray studies
5. Stability studies     
                                        PLAN OF W
ERY SYSTEM 
ORMULATION 
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keted formulation  
mance liquid chromatography (HPLC) metho
croscopy (SEM) 
 
ORK   
Page 78 
d. 
CHAPTER VII          
 
FLOATING DRUG DELIV
 
MAT
MATERIALS: 
S. NO NAME
 
1. 
 
Valsartan
 
2. 
 
HPMC (different 
 
3. 
 
Methyl Cellul
 
4. 
 
Ethyl cellulo
 
5. 
 
Lactose
 
6. 
 
Talc 
 
7. 
 
Magnesium Ste
 
8. 
 
Hydrochloric a
 
 All other chemicals 
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ERIALS AND EQUIPMENTS 
 SUPPLIER OF MAT
 
 
Gift sample from Dr. Reddys Lab. 
Ranbaxy, Gurgan & Tablets
 
 
grades) 
 
Gift samples from Shasun Pharm
Dr. Reddys Lab. Pvt. Ltd
 
ose 
 
Gift sample from Shasun Phar
 
se 
 
Gift sample from Dr. Reddys Lab
 
 
 
Central Drug House, (P)Lt
 
Nice Chemicals,(P)Ltd
arate 
 
Nice Chemicals,(P)Ltd
cid 
 
Nice Chemicals,(P)Ltd
were of Analytical Grade. 
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Pvt. Ltd., Hyderabad, 
 India, Chennai 
a, Pondicherry &      
., Hyderabad.  
ma, Pondicherry 
oratory, Hyderabad 
d., New Delhi  
., Kerala  
., Kerala  
., Kerala  
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EQUIPMENTS: 
S.NO 
 
1. Electronic W
 
2. Single Punch Tabl
 
3. UV Visible S
 
4. Digital Tablet Dis
 
5. Friability
 
6. Tablets hardne
 
7. Vern
 
8. X-
 
9. Differential Sc
 
10. Fourier Transform
 
11. High Performance
 
12. Scanning El
 
13. Environm
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NAME MANUFA
 
eighing Balance A & D Company
 
et Compression Machine Cadmach Mach
Ahma
 
pectrophotometer UV-1700 P
Shimadz
 
solution Test Apparatus Disso 2000, Lab
 
 Test Apparatus 
 
Indian Equipme
Mum
 
ss tester (Monsanto) Praveen Enterp
 
ier Caliper Linker
 
ray machine  
 
Stallion 20, Elp
Ltd.
 
anning Colorimeter DSC Q200
 
 Infrared Spectroscopy Shimadz
 
 Liquid Chromatography  Int L-C-GC Agil
 
ectron Microscopy Hitachi S
ental  Chamber HTC 3003, Inlab
Ltd., 
NTS    
Page 80 
CTURER 
 
 HR 200,  Japan 
 
inery Co. Pvt., 
dabad 
 
harmaspec,  
u, Japan 
 
 India, Mumbai 
 
nt Corporation, 
bai 
 
rises, Bangalore  
 
, Mumbai 
 
ro International 
, India 
 
, Mumbai 
 
 
u, Japan 
 
ent Model, Japan 
 
-3400, Japan 
 Equipments (P) 
India. 
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SYNONYM: 
 Valsartaani, 
 
STRUCTURE:    (Sean Sw
                      
 
SYSTEMATIC IUPAC N
 N - (1 - oxopentyl)
– L-valine  (Sean Sw
 
CHEMICAL FORMULA
 C24H29N5O3  (Sean S
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CHAPTER VIII 
DRUG PROFILE  
VALSARTAN 
Valsartan, Valsatanum (Sean C Sweetman et
eetman et al., 2009; Anthony C Moffat, 2004
AME: 
 – N - [2’- (1 – h – tetrazol – 5 - yl) [1, 1’- bip
eetman et al., 2009; Anthony C Moffat , 200
: 
weetman et al., 2009; Anthony C Moffat, 20
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 al., 2009). 
)   
 
henyl]   –   4 - yl] 
4).                        
04).                        
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DESCRIPTION:   
  Nature  
  Solubility 
    
  Melting poin
              Molecular w
 Log P (octanol/wate
Octanol/water partition coef
   pKa
    
CATEGORY: 
 Angiotensin II Rece
 Antihypertensive Ag
 
IDENTIFICATION:
 
 UV light absorption 
al., 2009). 
 
PHARMACODYNAMIC 
 Valsartan belongs to
and possess about 20,000
type 2 receptor (AT2).  This
as decreases vascular  smoo
renal function and also le
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  :  White microcrystalline pow
  :  Freely soluble in ethanol, 
  sparingly soluble in water.
t   :  105 - 110°C  
eight  :        435.519 g/mol 
r)   :        1.499 
ficient      : 0.033  
   : 3.9 & 4.7 (Nadeem Siddiqu
   
ptor Antagonists. 
ents (Jennifer Martin and Henry Krum, 2002
at 203, 248 nm (Nataraj K.S et al., 2011; Sea
PROPERTIES: 
 the family of angiotensin II type 1 receptor 
 fold greater affinities for it than for th
 action exert effects on blood pressure (BP) 
th muscle contraction, inhibits sympathetic o
ads to reduction in progression of athero
FILE  
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der 
methanol,   
 
i et al., 2011) 
; Drug bank). 
n C Sweetman et 
(AT1) antagonists 
e angiotensin II            
reduction, as well 
utflow, improves 
sclerosis lesions 
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(Jennifier Martin et al., 2
increase in local   angiotens
The increase in AT2 recept
of bradykinin which in tur
nitric oxide and cyclic gu
provides protection against 
 
PHARMACOKINETIC P
Absorption 
 Rapidly absorbed af
 T max is 2 hour for 
et al., 2007). 
Metabolism 
 Valsartan is not sig
metabolite, 4-OH-va
4-OH-valsartan acc
valsartan.  Although
drug interactions bet
Excretion  
 83% excreted in the 
 13% in urine as unch
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002). Also blockade of AT1 receptor by v
in II concentration that stimulates the unbloc
or stimulation causes vasodilatation through
n leads to signaling cascade the increases t
anosine 3’-5’-monophosphate at the endo
vascular dysfunction. 
ROPERTIES:
 
ter oral administration 
parent compound, 5 to 9 hour for metabolite
nificantly metabolized in humans.  The pr
lsartan, is pharmacologically inactive and pr
ounts for approximately 9% of the circ
 valsartan is metabolized by CYP2C9, CY
ween valsartan and other drugs are unlikely
feces via biliary excretion. 
anged drug (Mehtap Saydam et al., 2007).
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alsartan leads to 
ked AT2 receptor.  
 local production 
he production of 
thelial level that 
 (Mehtap Saydam     
imary circulating 
oduced CYP2C9.    
ulating dose of 
P-mediated drug-
 (Drug Bank). 
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PHARMACOKINETIC C
 Oral Bioavailability
 Half Life  
    
 Plasma protein bindi
 Volume of Distribut
 Excretion  
 
THERAPEUTIC INDICA
 Hypertension 
 Congestive Heart Fa
 Left ventricular dys
Henry Krum, 2002;
 
DOSING STRENGTH: 
 Hypertension: Initia
achieve desired effec
 Heart Failure : Ini
daily, as tolerated; m
 Left ventricular dys
target of 160mg twic
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HARACTERS OF VALSARTAN:  
  : 23 % with high variability. 
 : Initial phase t1/2  is <1 hou
  terminal phase t1/2β  is 5-9ho
ng : 94 to 97% mainly to albumi
ion : 17L 
 : 83% in feces, 13% in urine
TIONS & USAGE: 
ilure 
function Post-myocardial infarction (MI) (Je
 Mehtap Saydam et al., 2007). 
l 80mg or 160mg once daily (OD); dose ma
t; maximum recommended dose: 320mg. 
tial 40mg twice daily (BID); titrate dose to
aximum daily dose: 320mg. 
function after MI: Initial 20mg twice dail
e daily as tolerated (Access Medicine; Drug 
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r,  
ur. 
n. 
 (Drug Bank).  
nnifier Martin & 
y be increased to 
 80-160mg twice 
y; titrate dose to 
Bank). 
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ADVERSE EFFECTS:  
 Dizziness (11.7%) 
 Headache and Migra
 Epistaxis (0.5%) 
 Fatigue (10%) 
 Rash (1.1%) 
 Joint stiffness 
 Muscle cramps 
 Myalgia 
 Orthostatic hypotens
 Hyperkalemia (5%)
 Respiratory tract dis
 Nausea  
 Vomiting (1.4%) 
 Diarrhea 
 Dyspnoea 
 Dyspepsia 
 Oedema (Nadeem S
DRUG INTERACTIONS
 NSAIDS and Ciclo
hyperkalemia (Sean 
 General anesthetics
increased risk of hyp
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ine (10.3%) 
ion 
 
orders 
iddiqui et al., 2011). 
: 
sporin as it causes increased risk of renal
C Sweetman et al., 2009). 
, Clozapine, Dopamine agonists and other hy
otension. 
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 Hyperkalemia can 
diuretics, Potassium
et al., 2011) 
CONTRAINDICATIONS
 Severe hepatic impa
 Liver cirrhosis 
 Biliary obstruction
 Pregnancy 
 Lactation (Mehtap S
 
DIETARY IMPLICATIO
 Avoid salt substitut
food (Drug Bank; A
 
STORAGE & COMPATI
 Store at 25
0
C (77
0
F)
from moisture (Acce
 
GENERIC AVAILABLE
 NO 
 
FORMULATION TYPES
 Conventional dosage
 Pulsatile capsule dos
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be caused during valsartan therapy with P
 supplements, ACE inhibitors and Heparin 
:  
irment 
 
aydam et al., 2007). 
NS: 
es which contain potassium.  May be taken
ccess Medicine). 
BILITY: 
; excursions permitted to 15
0
C to 30
0
C (59
0
ss Medicine). 
: 
:  
 forms of tablets and capsules 
age form 
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otassium-sparing 
(Nadam Siddiqui       
 with or without 
F to 86
0
F). Protect 
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 Fast dissolving table
 
INTERNATIONAL BRAN
 Diovan® (U.S, Cana
 Varexan (Hung) 
 Diovan HCT (Venez
 Co-Diovan (Switz)
 Valaplex-D,Vartalan
 Diovan, Starval (Ind
  
ADDITIONAL INFORMA
 Valsartan may hav
requirements and 
(Drug Bank). 
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ts (Mehtap Saydam et al., 2007).  
D NAMES:  
da, and multiple international markets) 
) 
 
 D (Chile) 
ia) (Sean C Sweetman et al., 2009). 
TION 
e an advantage over losartan due to min
consequent use in mild-to-moderate hep
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imal metabolism 
atic impairment          
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HYDROX
Synonym:  
 Hypromellose 
 Methocel 
Structure: 
Empirical formula:  
 It is partly O-methy
It is available in s
substitution.  
Molecular weight: 
 10 000 – 1 500 000
Description:   
 Color: White or crea
 Odour: Odorless  
 Taste: Tasteless 
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EXCIPIENTS PROFILE
 
Y PROPYL METHYL CELLULOSE
(Raymond C. Rowe et al., 2006) 
lated and O-(2-hydroxy propylated) cellulos
everal grades depending upon the viscosi
 
my-white fibrous or granular powder. 
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e. (PhEur 2005).  
ty and extent of 
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Melting point:  
 190–200
0
C; chars at
Functional Category:   
 Coating agent. 
 Film- former. 
 Stabilizing agent. 
 Tablet binder. 
 Viscosity increasing
Typical Viscosity values fo
Methocel K100 Pre
Methocel K4M Pre
Methocel K15M Pr
Methocel K100M P
Methocel E4M Pre
Methocel F50 Prem
Methocel E10M Pr
Methocel E3 Premi
Methocel E5 Premi
Methocel E6 Premi
Methocel E15 Prem
Methocel E50 Prem
Metolose 60SH 
Metolose 65SH 
Metolose 90SH 
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 225–230
0
C. 
 agent. 
r 2 % (w/v) aqueous solutions of different
of HPMC at 20°C 
mium LVEP 
mium 
emium 
remium 
mium 
ium 
emium CR 
um LV 
um LV 
um LV 
ium LV 
ium LV 
100 
4000 
15000 
100 000 
4000 
50 
10 000 
3 
5 
6 
15 
50 
50, 4000, 10 000 
50, 400, 1500, 4000
100,400,4000, 15 00
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 viscosity grades 
 
0 
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Solubility: 
 Soluble in cold wate
 Practically insoluble
 Soluble in mixtures
 Soluble in mixtures 
 
Storage Conditions: 
 It should be stored in
 
Handling Precautions: 
 Hypromellose dust m
 Excessive dust gene
 Hypromellose is com
 
Regulatory status: 
 Included in the FDA
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ERY SYSTEM 
r, forming a viscous colloidal solution, 
 in chloroform, ethanol (95 %) and ether, 
 of ethanol and dichloromethane, 
of water and alcohol. 
 a well-closed container, in a cool, dry place
ay be irritant to the eyes and eye protection 
ration should be avoided to minimize the risk
bustible. 
 inactive ingredients. Recognized by GRAS 
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. 
is recommended 
s of explosion.  
status. 
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Synonym: 
 Benecel 
 Metolose 
 
Structure: 
 
Empirical formula:   
 Long-chain substitu
hydroxyl group in th
 
Molecular weight:   
 10 000 – 220 000 Da
Description:   
 Color: White, fibrou
 Odour: Practically o
 Taste: Tasteless. 
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ERY SYSTEM 
METHYL CELLULOSE  
(Raymond C. Rowe et al., 2006) 
ted cellulose containing approximately 27
e form of methyl ether. 
lton. 
s powder or granules. 
dorless and 
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 – 32 % of the 
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Melting Point: 
 190–200°C. 
Solubility:  
 Practically insoluble
saturated salt solutio
 In cold water, it swe
colloidal dispersion.
Functional Category:   
 Bulk laxative (5.0 
 Emulsifying agent (1
 Tablet binder (1.0 –
 Tablet Coating (0.5 
 Tablet and capsule
Storage Conditions: 
 It should be stored in
Handling Precautions: 
 Irritant to the eyes 
 Methylcellulose is c
 Spills of the dry po
slippery film that for
Regulatory status: 
 Included in the FDA
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ERY SYSTEM 
 in acetone, methanol, chloroform, ethanol (9
ns, toluene and hot water.   
lls and disperses slowly to form a clear to op
 
– 30.0 %). 
.0– 5.0 %), 
 5.0 %). 
-5.0 %). 
 disintegrate (2.0 – 10.0 %). 
 an airtight container in a cool, dry place. 
& eye protection should be worn.  
ombustible. 
wder or solution should be cleaned up im
ms can be dangerous. 
 inactive ingredients. Recognized by GRAS 
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5 %), ether,  
alescent, viscous, 
mediately, as the 
status. 
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Synonyms: 
 Aquacoat ECD 
 Aqualon 
 Ethocel 
 Surelease 
Structure: 
 
 
Empirical formula:   
 C12H23O6(C12H22O
Molecular weight:   
 40 0000 
Description: 
 Color: White to ligh
 Odour: Odorless. 
 Taste: Tasteless. 
                           EXCIPIENTS PROF
ERY SYSTEM 
ETHYL CELLULOSE  
(Raymond C. Rowe et al., 2006) 
5)nC12H23O5 
t tan colored powder. 
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Melting point: 
 165
0 
 - 185
0 
C 
Solubility: 
 Practically insoluble
 Freely soluble in chl
Functional Category: 
 Coating agent. 
 Flavouring fixative
 Tablet binder. 
 Tablet filler. 
 Viscosity-increasing
Storage Conditions: 
 It should be stored 
away from all source
Handling Precautions: 
 To prevent fine dust
levels in the air. 
 Its combustible 
 It may be an irritant 
Regulatory status: 
 Included in the FDA
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ERY SYSTEM 
 in propylene glycol, glycerine and water  
oroform, ethanol, ethyl acetate, methanol and
. 
 agent.  
at a temperature not exceeding 328
0 
C (90
s of heat. 
 clouds of ethyl cellulose from reaching pot
to the eyes and eye protection should be wor
 inactive ingredients. Recognized by GRAS 
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 toluene. 
0
F) in a dry area 
entially explosive 
n. 
status. 
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Synonym:   
 Lactopress Anhydro
 Lactosum. 
 Milk sugar. 
 
Structure: 
 
Empirical formula:  
 C12H22O11 
 
Molecular weight:  
 342.30 
 
Description:   
 White to off-white c
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LACTOSE  
(Raymond C. Rowe et al., 2006) 
us. 
 
rystalline particles or powder. 
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Melting Point: 
 223
0
 -252.2
0
 C 
 
Solubility:   
 Soluble in water,  
 Sparingly soluble in
 
Functional Category:  
 Binding agent. 
 Directly compressib
 Lyopholization aid.
 Tablet and capsule f
 
Storage Conditions: 
 It should be stored in
 
Handling Precautions: 
 Excessive generation
 
Regulatory status: 
 Included in the FDA
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 ethanol (95 %) and ether. 
le excipient. 
 
iller. 
 a well-closed container in a cool, dry place.
 of dust, or inhalation of dust, should be avo
 inactive ingredients. Recognized by GRAS 
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ided. 
status. 
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Synonyms: 
 Powdered talc. 
 Purified French chal
 Soapstone. 
 
Structure: 
 
 
Empirical formula: 
 Mg6(Si2O5)4(OH)
 
Description: 
 Appearance: Very fi
 Color: White to gray
 Odour: Odorless, im
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ERY SYSTEM 
TALC  
(Raymond C. Rowe et al., 2006) 
k. 
 
4 
ne, unctuous, crystalline powder. 
ish-white. 
palpable. 
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Solubility: 
 Practically insoluble
 
Storage Conditions: 
 It should be stored in
 
Functional Category: 
 Anti caking agent. 
 Glidant. 
 Lubricant. 
 
Handling Precautions: 
 Talc is irritant if
pneumoconiosis. 
 
Regulatory Status: 
 Included in the FDA
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 in dilute acids and alkalis, organic solvents, 
 a tightly closed container in a cool and dry 
 inhaled and prolonged excessive expo
 inactive ingredients. Recognized by GRAS 
ILE   
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and water. 
place. 
sure may cause 
status. 
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Synonyms: 
 Magnesium octadec
 Octadecanoic acid.
 Magnesium salt. 
Structure: 
 
 
Empirical formula: 
 C36H70MgO4 
 
Molecular Weight: 
 591.34 
 
Melting Point: 
 117–150
0
C (comme
 126–130
0
C (high pu
                           EXCIPIENTS PROF
ERY SYSTEM 
MAGNESIUM STEARATE 
(Raymond C. Rowe et al., 2006) 
anoate.  
 
rcial samples). 
rity magnesium stearate). 
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Page 99 
 
CHAPTER IX             
 
FLOATING DRUG DELIV
 
 
Description: 
 It is a very fine pow
 
Solubility: 
 Insoluble in ethanol,
 Slightly soluble in w
 
Storage Conditions: 
 It is stable and shoul
 
Functional Category: 
 Tablet and capsule l
 
Handling Precautions: 
 Eye protection and g
 Excessive inhalation
discomfort, coughin
 Magnesium stearate
respirator is recomm
 
Regulatory Status: 
 Included in the FDA
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ERY SYSTEM 
der. 
 ether and water. 
arm benzene and warm ethanol 95%. 
d be stored in a well closed container, in a co
ubricant. 
loves are recommended.  
 of magnesium stearate dust may cause uppe
g, and choking.  
 should be handled in a well ventilated
ended. 
 inactive ingredients. Recognized by GRAS 
ILE   
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ol, dry place. 
r respiratory tract 
 environment; a 
status. 
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I. STANDARD CALIBRA
(a) Preparation of dissolut
    0.1N Hydrochloric Acid:
Dissolve 8.5ml of c
get 0.1N hydrochloric acid
(b) Determination of (Abs
UV spectrum is obt
buffer solution (0.1N hydro
(c) Preparation of standar
A known quantity o
small quantity of methanol 
this primary stock solutio
hydrochloric acid. From thi
10, 12, 14, 16, 18, 20µg/ml 
The absorbance of 
Spectrophotometer (Shimad
acid as blank. The standa
absorbance in Y-axis. The 
of drug released during the 
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CHAPTER X 
PERIMENTAL PROTOCOL 
TION CURVE OF VALSARTAN 
ion medium:   
 
oncentrated hydrochloric acid in 1000ml of 
 (Mahajan P et al., 2011; Marget Chandira et 
orption Maximum)  λmax   by UV Spectrum
ained for 10µg/ml concentration of valsarta
chloric acid).  
d calibration curve for valsartan: 
f valsartan (50mg) is accurately weighed a
and made upto 50ml with the 0.1N hydroch
n 10ml is pipette out and made upto 1
s secondary solution aliquots are taken to 
and diluted to 100ml with 0.1N hydrochloric
the resulting solution is measured at 204nm
zu UV-1700 Pharma spec, Japan) using 0
rd curve is plotted by taking concentratio
calibration curve is used for the estimation of
in vitro dissolution studies (Sevgi tatar et al
TOCOL  
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distilled water to 
al., 2009). 
: 
n using standard 
nd dissolved in a 
loric acid.  From 
00ml with 0.1N 
produce 2, 4, 6, 8, 
 acid.   
 by UV-Visible 
.1N hydrochloric 
n in X-axis and 
 the concentration 
., 2002). 
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II. PREFORMULATION
The compatibility 
the drug and polymer intera
(a) Differential Scanning
DSC is performed
calibrated with indium stand
Kachrimanis et al., 2011)
Thermo grams are obtain
10
0 
C/minute. A dry purge
heated from 37°C -400°C 
(b) Fourier Transform Infr
The possibility of d
The FT-IR graph of pure dr
analysis is performed by u
range is 450-4000 cm
-1 
and
(Debajyoti Ray et al., 20
Mandapalli et al., 2012). 
 
III. FORMULATION OF
Non-effervescent fl
direct compression techni
polymers. All the ingredien
sieves accordingly.  Then, 
uniformly in glass mortar. 
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 (COMPATABILITY) STUDIES: 
studies are carried out by DSC and FT-IR in 
ction. 
 Calorimetric (DSC) Studies:
 
                    
 using DSC Q200 Thermal Analyzer. Th
ard. Accurately weighed (it varies from 3mg
 samples are placed in an open type ceram
ed by heating the sample at a constant
 of Argon gas (25ml/min) is used for all 
(Mahajan P et al., 2011). 
ared Spectroscopic (FT-IR) Studies: 
 
rug-excipient interactions are further invest
ug and combination of drug with excipient 
sing FT-IR Spectrometer (Shimadzu, Japa
 the resolution is 4cm
-1
. Samples are prepar
10; Kyriakos Kachrimanis et al., 2011; 
 VALSARTAN FLOATING MATRIX TA
oating matrix tablets containing valsartan
que using varying concentrations of dif
ts are accurately weighed and passed throug
except magnesium stearate all other ingred
After sufficient mixing of drug as well as o
TOCOL  
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order to evaluate 
e instrument is 
-5mg) (Kyriakos 
ic sample pans. 
 heating rate of              
runs. Samples are 
igated by FT-IR. 
are recorded. The 
n). The scanning 
ed in KBr pellets 
Praveen Kumar 
BLETS: 
 are prepared by 
ferent grades of 
h different mesh 
ients are blended 
ther components, 
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magnesium stearate and tal
2-3 minutes. 250mg of pow
tablets by using a single pu
the tablets are kept constan
 
IV. EVALUATION OF V
      1. PRECOMPRESSIO
(a) Angle of repose
The frictional forces
repose. This is the maximu
granules and the horizonta
allowed to flow through th
repose is then calculated b
formed (Ajay Bagherwal 
al., 2009). 
 
Where,  
 θ = angle of
 h = height o
 r = radius of
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ERY SYSTEM 
c is added, as post lubricant, and further mix
der blend is weighed and compressed int
nch tablet machine (Cadmach, Ahmedabad
t for all formulation (Pare A et al., 2008).  
ALSARTAN FLOATING MATRIX TABL
NAL EVALUATION OF POWDER BLE
 (θ):  
 in a loose powder or granules can be meas
m angle possible between the surface of a p
l plane (Natasha Sharma et al., 2011). 
e funnel fixed to a stand at definite height 
y measuring the height and radius of the 
et al., 2010; Leon Lachman et al., 2009; Ma
tan θ = h/r 
θ = tan
-1 
(h/r) 
 repose 
f the heap 
 the heap 
TOCOL  
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ed for additional 
o 10mm biconvex 
). The weights of 
ET: 
ND:  
ured by angle of 
ile of powder or 
 The granules are 
(h). The angle of 
heap of granules 
rgret Chandira et 
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The relationship betw
Angle
 
(b) Bulk density: 
 
Bulk density is the 
Apparent bulk density is d
cylinder via funnel and m
Chandira et al., 2009).  Den
                                           
                         Bulk densit
                                          
 
(c) Tapped density
Tapped density is th
final volume of powder aft
containing a known mass o
has reached a constant valu
The tapped density is compu
                                            
                  Tapped density
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ERY SYSTEM 
een Angle of repose and powder flow is as 
 of Repose Powder flow 
< 25° Excellent 
25°- 30° Good 
30°- 40° Passable 
>  40° Very Poor 
ratio between a given mass of powder and 
etermined by pouring the weighed granules
easuring the volume (Natasha Sharma et a
sity is calculated by using the formula,  
    Mass of the powder   
y =     ---------------------------------------    =   
          Bulk volume of the powder  
:   
 
e ratio between a given mass of powder an
er tapping.  It is determined by tapping a g
f granules for a fix number of taps until th
e (Natasha Sharma et al., 2011; Shyamala B
ted by using the formula, 
                  Mass of the powder   
 =    -------------------------------------------------
          Minimum (tapped) volume of the po
TOCOL  
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follows in table. 
its bulk volume.  
 into a graduated 
l., 2011; Margret 
 W 
   ------                      
 Vo 
d the constant or 
raduated cylinder 
e powder volume 
haskaran, 2010).  
   M 
----   =    ------                   
wder   Vf 
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 (d) Compressibility
The flow ability of 
and tapped density (ρt) of p
et al., 2011) Compressibility
Compressib
 
Where, 
   ρo = Bulk de
ρt = Tapped d
 
 Values of I: (Debajyoti Ra
Compr
 
(e) Hausner’s Ratio
 The Hausner’s ratio 
granular material (Debajyo
Chandira et al., 2009). It is 
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 Index: (I)  
powder can be evaluated by comparing the 
owder and the rate at which it packed down
 index is calculated by using the formula, 
ρt 	– ρo 
ility Index (%)   =       -----------------     x 10
        ρt 
nsity g/ml. 
ensity g/ml. 
y et al., 2010; Shyamala Bhaskaran, 2010) 
essibility Index Type of flow 
5-15% Excellent 
15-25% Good 
>25% Extremely poor 
: 
is a number that is correlated to the flowabili
ti Ray et al., 2010; Shyamala Bhaskaran
calculated by the formula, 
TOCOL  
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bulk density (ρo) 
 (Natasha Sharma 
0 
 
ty of a powder or 
, 2010; Margret 
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Where,    
ρo = Bulk de
               ρt = Tapped d
The values less than
1.25 indicates poor flow (=
improves flow. 
(f) Estimation of dru
10mg drug equivale
volume is made up to 100
10ml of filtrate is diluted to
The absorbance of the 
UV spectrophotometer and 
2. POSTCOMPRESSION
TABLET:  
 (a) General appearance: 
The formulated tab
appearance (Leon Lachman
(b) Hardness:
 
Hardness indicates 
handling. The hardness of 
                     EXPERIMENTAL PRO
ERY SYSTEM 
     ρt 
Hausner ratio = -------- x 100 
      ρo 
nsity g/ml. 
ensity g/ml. 
 1.25 indicate good flow (= 20% Carr), whe
 33% Carr). Between 1.25 and 1.5, added 
g content for powder blend:  
nt of powder blend is dissolved in 10ml of 
ml with 0.1N hydrochloric acid. The soluti
 100ml with 0.1N hydrochloric acid (Arunku
resulting solution is measured at λmax
the drug content is estimated. 
AL EVALUATION OF VALSARTA
lets are evaluated for general appearance V
 et al., 1987). 
the ability of a tablet to withstand mechani
the tablets is determined by using Monsant
TOCOL  
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reas greater than 
glidant normally 
methanol and the 
on is filtered and 
mar et al., 2008).  
 (204nm) using                           
N FLOATING 
iz color, shape, 
cal shocks while 
o hardness tester     
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(Leon Lachman et al., 1987
and hardness of the tablets 
(c) Thickness and Diamete
Thickness of the ta
material to be compressed a
2010) is used to measure t
Three tablets are randomly 
tablets are determined. Bot
value. 
(d) Friability Test: 
 
The friability of tabl
percentage (%). Twenty 
friabilator.  The friabilator i
(Debajyoti Ray et al., 2010
The tablets are weighed aga
 
 
      
                      Percentage 
 
Percentage friability
1987). 
 (e) Weight variation Test
Twenty tablets are
individually and the averag
                     EXPERIMENTAL PRO
ERY SYSTEM 
). It is expressed in kg/cm
2
. Three tablets are
is determined (Debajyoti Ray et al., 2010). 
r: 
 
blet mainly depends upon the filling, phys
nd compression force. Vernier caliper (Mina
ablet thickness and diameter (Natasha Shar
picked from each batch and the thickness an
h should be controlled within a ±5% variat
ets is determined by using Roche Friabilator
tablets are initially weighed (W initial) and
s operated at 25rpm for 4 minutes or run up t
; Margret Chandira et al., 2009; Mina Ibrahi
in (W final).  The % friability is then calculate
            Initial weight 	 Final weight 
Friability = ---------------------------------------
Initial weight 
 of tablets <1% was considered acceptable
:
  
 selected randomly from each formulati
e weight is calculated as per I.P method.  N
TOCOL  
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 randomly picked 
ical properties of 
 Ibrahim Tadros, 
ma et al., 2011).  
d diameter of the 
ion of a standard 
. It is expressed in 
 transferred into 
o 100 revolutions         
m Tadros, 2010). 
d by,  
 
   x 100 
 (Leon Lachman, 
on and weighed                           
ot more than two 
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tablets should deviate from
more than twice that percen
The following perc
(Margret Chandira et al., 20
Average W
80m
More than 80mg
250m
 
(f) Estimation of drug cont
10 mg drug equiva
methanol, made up to 100m
is made up to 100ml with 0
above solution and analyze
(Arunkumar N et al., 2008).
3. IN VITRO BUOYANCY
The tablets are plac
maintained at 37°C (Shreera
required for the tablet to ri
and the time period up to
floating time (Arunkumar N
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 the percentage as given in IP and none s
tage (Ajay Bagherwal et al., 2010).   
entage deviation in Weight Variation is
09; IP 2007).
 
eight of a tablet Percent Devi
g or less ±10%
 but less than 250mg ±7.5%
g or more ±5% 
ent for tablets:  
lent of the powdered formulation is diss
l with 0.1N hydrochloric acid and filtered. 1
.1N hydrochloric acid. 10µg/ml solution is p
d for drug content by UV spectrophotometer
       
 STUDIES:
  
ed in a beaker containing 100ml of 0.1N
j H. Shah et al., 2010; Sakarkar D. M. et al
se to the surface and float is determined as 
 which the tablet remained floating is de
 et al., 2008; Praveen Kumar N et al., 2008
TOCOL  
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hould deviate by 
 shown in table 
ation 
 
 
olved in 5ml of 
0ml of the filtrate 
repared from the 
 at a λmax 204 nm 
 hydrochloric acid 
., 2010).  The time 
floating lag time 
termined as total 
). 
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4. SWELLING STUDIES:
The swelling behavi
water uptake.  The dimens
tablet diameter and/or thick
and dissolution of floating 
2009). Swelling index of ta
and placed in a beaker cont
(Mina Ibrahim Tadros, 201
blotted with filter paper to
Water uptake is measured 
(Sakarkar et al., 2010; Deba
      Swelling
 
 
Where, 
Wt = weight of table
Wo = weight of table
 
5. IN VITRO RELEASE S
In vitro release stud
hours. The tablets are place
in the dissolution apparatu
(Mahajan P et al., 2011; P
withdrawn at every 15 min
for the next 11hours. The s
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or of a dosage form is measured by studying 
ional changes could be measured in terms o
ness over time. Swelling is a vital factor to
matrix tablet (Shishu et al., 2007; Margre
blet is determined for each formulation; tab
aining 200ml of 0.1N hydrochloric acid at r
0).  After each hour the tablet is removed 
 remove excess of water and weighed agai
in terms of percent weight gain, as given
jyoti Ray et al., 2010).
 
Wt	– W0 
 Index (%) = -------------------- x100 
       W0 
t at time t hour 
t before immersion 
TUDIES: 
 
ies are performed in USP type II paddle 
d in the dissolution medium of 900 ml 0.1N
s. The paddle is rotated at 50 rpm maintai
raveen Kumar Mandapali et al., 2012). 
utes intervals for the first hour and every 30 
ame volume of buffer solution is replaced in
TOCOL  
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its weight gain or 
f the increase in 
 ensure buoyancy 
t Chandira et al., 
lets are weighed 
oom temperature 
from the beaker, 
n upto 12 hours.  
 by the equation 
apparatus for 12 
 hydrochloric acid 
ned at 37 ± 5°C 
 5 ml samples are 
minutes intervals 
to the dissolution 
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medium.  The withdrawn s
Samples are analyzed at 20
Kumar Nayak et al., 2011)
SUMMARY O
Parame
Dissolution m
Temperat
Initial Vol
Rotation s
Drawn Vo
Running t
Medium Repl
 
6. INVITRO DRUG RELE
In controlled or su
controlling mechanisms are
 Diffusion 
 Swelling  and 
 Erosion  
The In vitro release 
order, first order, Higuchi, 
out the mechanism of drug 
2011). 
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amples are diluted up to 50ml with 0.1N h
4 nm using UV spectrophotometer (USP 30
. The studies are done in triplicate.  
 
F GENERAL DISSOLUTION CONDITI
ter Specifications 
edium Buffer 0.1N hydrochloric a
ure 37.0 ± 0.5 °C 
ume 900ml 
peed 50rpm 
lume 5ml 
ime 12 hrs in 0.1N hydrochloric a
acement Media refilling at every 30 m
ASE KINETICS STUDIES: 
 
stained release formulations the three mo
,  
profiles obtained from the floating tablets 
Hixson Crowell, Korsemeyer & Peppas mode
release (Pramod Patil et al., 2011; Amit Ku
TOCOL  
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ydrochloric acid. 
-NF, 2007; Amit 
ONS 
cid 
cid 
in. 
st important rate 
were fitted to zero 
l kinetics, to find 
mar Nayak et al., 
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Release 
Ze
Fi
Hixs
Korsm
    
Fitness of release
coefficients of determinatio
For cylinder type 
Mandapali et al., 2012). 
Diffusion Exponent (n)
n < 0.45 
n=0.45 to 0.89 
n=0.89 
n> 0.89 
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Kinetics Model Equation 
ro Order Qt = Q0 + K0.t 
rst Order In Qt = In Q0 + K0.t
on-Crowell  Q0
1/3
 - Qt
1/3
 + K.t 
Higuchi Q = KH. t
1/2
 
eyer - Peppas Mt / M0 = a.tn 
 
 profiles to linear equations is assessed b
n (r) values. 
of systems, (Harris Shoaib et al., 2006
 Overall Solute Diffusion Me
Classical Fickian diffus
Anomalous Non Fickian transport i
diffusion in the hydrated matrix and p
(Indicators of both phenomenon) 
Case II relaxation release transpo
release (Polymer relaxation or sw
systems) 
Super Case II transpo
TOCOL  
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y comparing the 
; Praveen Kumar 
chanism 
ion 
.e. coupled drug 
olymer relaxation 
rt - zero order  
elling controlled 
rt 
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The in-vitro release
applying data are, 
 Cumulative % drug 
 Log cumulative of 
 Cumulative % drug 
 Log cumulative % d
 Cube root of drug %
law. 
 
V. SELECTION OF BEST
The best formulatio
behavior, Invitro release stu
A) EVALUATION OF BE
1. COMPARISON WITH M
  The release of the b
(Pare A et al., 2008; Mahaja
2. ASSAY BY HPLC METH
Quantitative determ
chromatography method (H
2010; Ziyaur Rahman et al
mortar and pestle.  Exact a
methanol upto 50ml in a vo
through 0.45µm filter pape
after appropriate dilution of
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 data are fitted to the above mathematical
release vs. time for zero order kinetic.  
% drug remaining vs. time for first order kinet
release vs. Square root of time for Higuchi m
rug release vs. log time for Korsmeyer-peppa
 remaining in matrix vs. time for Hixson
 FORMULATION: 
n is selected depending on the results obtain
dies and kinetic analysis. 
ST FORMULATION 
ARKETED FORMULATION 
est formulation is compared with the mark
n P et al., 2011). 
OD 
ination of valsartan is performed by high pe
PLC-Int L-C-GC Agilent Model) (Ramesh C
., 2006). Fifteen tablets are taken and crushe
mount of powder (average weight) is taken
lumetric flask.  After sonication for 15mts, s
r. The total amount of drugs within the tab
 test solution by using the HPLC method as
TOCOL  
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 models and the 
ic.  
odel. 
s model and  
-Crowell cube root 
ed from floating 
eted formulation               
rformance liquid 
. Nagarwal et al., 
d to powder with 
 and diluted with 
olution is filtered 
lets are analyzed 
 described below 
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against the reference soluti
(Liandong Hu et al., 2010 ; 
 Column : Stainless 
                              bonded to
 Mobile Phase : A 
0.1 
2007
 Detector: UV detec
 Injection Volume:
 Flow Rate: 1ml per
 
3. SCANNING ELECTRO
The SEM image o
texture and morphology of 
of drug release and floating.
The surface of the ta
accomplished by placing the
them to remove water conte
are coated with a gold-palla
(Vandana Jugran et al., 201
to 10KV.  Study of the mo
information about the 3-D s
Imaging is done at a magni
2010; Manoj N et al., 2007)
                     EXPERIMENTAL PRO
ERY SYSTEM 
on of valsartan pure powder prepared in the
Gendle R et al., 2010 ; Uttam Mandal et al., 
steel column (25cmx4.6mm) and packed with
 porous silica (5µm particle size). 
mixture of 50 volumes of water, 50 volumes o
volumes of glacial acetic acid (50:50:0.1) 
).       
tion with 273nm (UV-Visible Spectrophotom
 10µl. 
 minute.   
N MICROSCOPY 
f the tablet has been used to examine sur
fractured surface are compared to hypothesiz
   
blets is studied by SEM.  The preparation o
 intact tablets before and after 12 hours disso
nt and placing these tablets on specimen hol
dium target using a Novatec vaccum evapora
1).  SEM images are obtained at an accelera
rphology of the particles using SEM is done
tructure of the particles with the resolution 
fication of 200µm and pressure of 0.98 torr
. 
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 same procedure 
2007) 
 octadecylsilane    
f acetonitrile and 
(USP 30-NF 25,      
etric-Shimadzu). 
face topography; 
e the mechanism 
f the samples are 
lution, by drying 
der.  The samples 
tor for 15minutes 
tion voltage of 8 
, which provides 
power up to 5
0 
A. 
 (Anilkumar et al., 
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4. In vivo X – RAY STUDIE
The in vivo studi
Reference No. 14024/E1/4
2-2.5 kg. The animal i
(Londhe S et al., 2010).  Th
administering the tablets b
syringes.  
The tablets are made
drug.  The rabbit is exposed
are taken at 0, 2, 4, 6, 8, 10
ml of 5% dextrose solutio
(Dinesh Kumar et al., 2010)
 
5. STABILITY STUDIES:
Stability studies are
the result of aging and stora
floating matrix tablet is sub
at temperature of 40
0
C ± 2
chamber for a period of 
Mayur N et al., 2010; Pram
appearance, hardness, float
interval. 
 
                     EXPERIMENTAL PRO
ERY SYSTEM 
S:   
es approved by Institutional Animal Et
/2011 and are performed on healthy albino
s fasted overnight but allowed to take w
en 30 ml of 5 % dextrose solution is given im
y using stomach tube (No. 12 French cath
 opaque by incorporating barium sulphate 
 to X-ray imaging in the abdominal region,
 & 12 hrs after administration of tablet. At h
n is given to maintain optimum fluid leve
.  The gastric residence time is observed. 
  
 performed as per the ICH and WHO guidel
ge under various conditions. The best formul
jected to stability studies. The optimized form
0
C and relative humidity of 75% ± 5% in
three months (Mina Ibrahim Tadros et a
od Patil et al., 2011).  The formulation is
ing lag time and drug content analysis at 
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hical Committee 
 rabbit weighing     
ater ad libitum           
mediately before 
eter) and 20 ml 
(BaSO4) instead of 
 and photographs 
ourly intervals 30 
l in the stomach 
ines to determine 
ation of valsartan 
ulation is stored 
 an environmental 
l., 2010; Jadhav       
 evaluated for its 
every one month 
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R
I. STANDARD CALIBRA
(a) Preparation of dissoluti
The preparation of d
acid.  
(b) Determination of (Abso
The λmax of valsart
solution in 0.1N hydrochlo
acid. The λmax of valsartan w
(c) Preparation of standard
Linear correlation 
0.1N hydrochloric acid.  V
2 to 20 µg/ml.  The correlat
of valsartan in 0.1N hydroch
II. PREFORMULATION
(a) Differential Scanning C
The DSC studies we
The DSC thermo grams of p
The DSC thermo g
indicating the melting point
of the drug (Nadeem Siddi
melting point of pure drug
                        RESULTS & DISCUS
ERY SYSTEM 
CHAPTER XI 
ESULTS AND DISCUSSION 
 
TION CURVE OF VALSARTAN:  
on medium:   
issolution medium was prepared by using 0
rption Maximum)  λmax   by UV Spectrum: 
an was determined by scanning the 10µg
ric acid.  It showed the λmax at 204nm in 0
as showed in UV spectrum (Figure: 1). 
 calibration curve for valsartan: 
coefficient was obtained for calibration 
alsartan obeys the Beer’s law within the co
ion coefficient was found to be γ = 0.99980
loric acid was shown in Table: 1 & Figure:
 (COMPATABILITY) STUDIES: 
alorimetric (DSC) Studies:
 
                    
re carried out to detecting the drug-polyme
ure drug & different polymers were shown i
rams of pure drug valsartan showed an e
 105 - 110°C which is in total agreement wi
qui et al., 2011). An endothermic peak corr
 was prominent in all the drug-polymer mi
SION   
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.1N hydrochloric 
/ml of the drug 
.1N hydrochloric 
of valsartan in                     
ncentration range               
.  Calibration plot 
 2.  
r incompatibility. 
n the Figure: 3. 
ndothermic peak 
th literature value 
esponding to the 
xture.  From this 
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observation we can draw a c
with the polymers. 
(b) Fourier Transform Infr
FT-IR studies were
and polymers. The spectra 
FT-IR spectrum of the drug
IR spectrum of pure drug w
the positions of characterist
The FT-IR Spectra o
S. NO 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
All the major bands
in the spectrum of polymer
suggests that the pure drug 
between the drug and polym
                        RESULTS & DISCUS
ERY SYSTEM 
onclusion that the drug is not showing any t
ared Spectroscopic (FT-IR) Studies: 
 
 carried out to confirm the compatibility be
obtained from the FT-IR studies from 450
 & polymers were shown in the Figure: 4. T
ith IR spectra of polymers showed no appr
ic absorption band.   
f pure drug valsartan shows as follows, 
CHARACTERISTICS WAV
N-H Stretching 
C-H Stretching in Alkane 
C=O Stretching 
Ar C=C Stretching 
Isopropyl Stretch 
CH3 Bending 
C-N Stretching 
C-C Stretching 
p- substituted benzene 
 present in the spectrum of the pure drug are
s with negligible changes in their position. 
remains in its normal form and hence there w
er. 
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ype of interaction 
tween pure drug 
-4000 cm
-1 
. The  
he comparison of 
eciable change in 
ENUMBER (
cm-1
) 
3443.05 
2964.69 
1730.21 
1600.97 
1469.81 
1410.01 
1274.99 
1205.55 
852.56 
 clearly observed 
This study clearly 
as no interaction 
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III. FORMULATION OF
The valsartan floati
using the hydrophilic and h
well established in the sim
properties respectively.  Fro
the floating behavior of the
2A & 2B.  It was foun
concentration of 20-75% 
HPMC K15M, HPMC K4M
floating behavior at concent
ethyl cellulose showed bette
The floating lag tim
the formula was optimized
IV. EVALUATION OF V
      1. PRECOMPRESSIO
The powder blend o
parameters such as angle o
Hausner’s ratio, and percent
(a) Angle of repose (θ):  
The angle of repose 
of 27º.08’ to 30º.26’, which
were shown in Table: 3A &
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ERY SYSTEM 
 VALSARTAN FLOATING MATRIX TA
ng matrix tablets were prepared by non-eff
ydrophobic polymers. Both polymers were c
ilar studies and have great swelling and 
m the trial studies, the formula was optimiz
 tablets and the optimized formulas were gi
d that the tablets showed good floating 
of the polymers. Various grades of  HPMC 
), and their combination with ethyl cellulo
ration 80%, while methylcellulose and their 
r floating behavior at concentration 75%. 
e was inversely related to the concentration
 accordingly. 
ALSARTAN FLOATING MATRIX TABL
NAL EVALUATION OF POWDER BLE
f all the formulations was evaluated for th
f repose, bulk density, tapped density, comp
age drug content. 
for the formulated powder blend was found 
 indicates good flow properties of powder b
 3B & Figure: 5A. 
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BLETS: 
ervescent method 
hosen as they are 
sustained release 
ed depending on 
ven in the Table: 
behavior at the 
(HPMC K100M, 
se showed better 
combination with 
 of polymers and 
ET: 
ND:  
e precompression 
ressibility index, 
to be in the range 
lend.  The results 
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(b) Bulk density: 
 
The bulk density of
g/ml, which indicates that t
Table: 3A&3B & Figure: 5
(c) Tapped density:    
 
The tapped density 
g/ml. The results were show
(d) Compressibility Index: 
Compressibility ind
indicates that the powder b
results were shown in Table
(e) Hausner’s Ratio: 
The Hausner’s ratio 
which indicates good flow
Table: 3A &3B & Figure: 5
(f) Estimation of drug cont
The percentage dru
between 98.32% to 99.79
shown in Table: 3A&3B. 
From the above resu
good flow properties of t
compressibility index value
density and hardness were
                        RESULTS & DISCUS
ERY SYSTEM 
 the powder blend was in the range of 0.2
he powder blend were not bulky.  The resul
B. 
of the powder blend was in the range of 0.2
n in Table: 3A &3B & Figure: 5C. 
(I)  
ex were found to be in between 14% to
lend have the required flow property for c
: 3A &3B & Figure: 5D. 
of the powder blend was found to be in the ra
 properties of powder blend.  The results
E. 
ent for powder blend:  
g content for F1 to F20 formulations wer
%, ensured the uniformity of drug content. 
lts it was concluded that the angle of repos
he powder blend.  This was further sup
s (<25%) results in good to excellent flow pr
 often interrelated properties.  In addition, pow
SION   
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50 g/ml to 0.367 
ts were shown in           
90 g/ml to 0.480 
 25.03%, which 
ompression. The 
nge 1.16 to 1.25, 
 were shown in    
e found to be in 
 The results were 
e (< 30º) indicate 
ported by lower 
operties.  Powder 
der density may 
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influence compressibility,
results indicate that the pow
properties (Amit K. Jain et
2. POSTCOMPRESSION
TABLET:  
Tablets of differen
general appearance, hardne
content. 
(a) General appearance: 
The formulated tabl
scoring on any sides. All ta
Table: 4A & 4B. 
(b) Hardness:
 
The hardness of all 
found to be in the range of
an ability to withstand phys
were shown in Table: 4A &
(c) Thickness and Diamete
The thickness and 
caliper and were ranged be
uniform particle size distrib
& 4B. 
 
                        RESULTS & DISCUS
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 tablet porosity, dissolution, and other prop
der blend of all the formulations possessed
 al., 2011). 
AL EVALUATION OF VALSARTA
t formulations were subjected to evaluati
ss, thickness, diameter, friability, weight v
ets were white color, biconvex and round sh
blets were elegant in appearance. The resul
the formulations were measured by Monsan
 3.5 – 4 kg/cm
2
, which indicates good mechan
ical and chemical stress conditions while han
 4B. 
r: 
 
diameter of all the formulations were mea
tween 3.5 – 4mm & 10mm, indicates that t
ution and no deformity. The results were sh
SION   
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erties.  All these 
 satisfactory flow 
N FLOATING 
on tests such as 
ariation and drug 
aped without any 
ts were shown in 
to tester and was 
ical strength with 
dling. The results 
sured by vernier 
he tablets having 
own in Table: 4A 
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(d) Friability Test: 
 
The percentage friab
The percentage friability w
mechanical resistance of the
indicates good handling p
Table: 4A & 4B. 
(e) Weight variation Test:
The weight variation
pharmacopeia. All the form
percentage weight variation
and hence all the formulatio
per I.P. The results were sho
(f) Estimation of drug cont
The percentage drug
99.16% to 99.89%, show
formulations. Hence the pe
official specifications as pe
The results were shown in 
From the above 
acceptable pharmacopeia 
for weight variation, drug c
2007).   
 
                        RESULTS & DISCUS
ERY SYSTEM 
ility of all the formulations were in between
as less than 1% in all the formulations, whi
 tablet.  The values of Hardness test and Pe
roperty of prepared tablets. The results 
  
 tests were performed according to the proce
ulated (F1 to F20) tablets passes weight va
 was within the pharmacopoeia limits of  
ns passes the weight variation within the ac
wn in Table: 4A & 4B.  
ent for tablets:  
 content of all the formulations were withi
ed that the drug was uniformly distrib
rcentage drug content of all the formulatio
r U.S.P (Limits: not less than 90% and not m
Table: 4A, 4B & Figure: 5F. 
results, it was concluded that all the form
properties and complied with the pharmacop
ontent, and friability (Amit K. Jain et al., 20
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 0.13% to 0.50%.  
ch indicates good 
rcentage friability 
were shown in        
dure given in the 
riation test as the 
±5% of the weight 
ceptable limits as 
n the range from 
uted in all the 
ns complies with 
ore than 110%). 
ulations showed 
eia specifications 
11; U.S.P 30 NF 
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3. IN VITRO BUOYANCY
The time taken for
Floating Lag Time (FLT) o
which dosage form remain
al., 2009; Riteshkumar et al
Among the twenty 
grades of HPMC (HPMC
combined with ethyl cellulo
The formulation 
10minutes.  The formulatio
and ethyl cellulose) had a 
buoyant upto 24hours. The 
With reference to b
containing HPMC polymers
floating lag time when com
its combination with ethyl
polymer which is governed 
dissolution fluid and the 
Nagarwal et al., 2010).   
4. SWELLING STUDIES:
Swelling study was
results of swelling index w
swelling index against time
                        RESULTS & DISCUS
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 STUDIES:
  
 a dosage form to emerge on the surface o
r Buoyancy Lag Time (BLT) and total du
s buoyant is called Total Floating Time (TF
., 2010; Margret Chandria et al., 2009). 
formulations, the formulations F1 – F15 (
 K100M, HPMC K4M, & HPMC K15M
se) Floated immediately.   
F16 (containing methylcellulose alone) had
ns F17 – F20 (containing the Combination o
lag time of 3 – 10 minutes.  All the formu
results were shown in Table: 5A & 5B & Fig
uoyancy studies results it can be conclude
 alone and its combination with ethyl cellul
pared to batch containing methylcellulose po
 cellulose. The buoyancy of the tablet varies
by both the swelling of the hydrocolloid upo
presence of voids in the centre of the ta
 
 
 performed on all the batches (F1 – F20) f
ere given in the Table No: 6A & 6B. Whi
 (hr) is shown in Figure: 7 & 8. 
SION   
Page 121 
f medium called 
ration of time by 
T) (Ravikumar et 
containing various 
) alone and it’s 
 a lag time of 
f methylcellulose 
lations remained 
ure: 6.  
d that the batch 
ose showed good 
lymers alone and 
 from polymer to 
n contact with the 
blet (Ramesh C. 
or 12hours.  The 
le the plot of the 
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Swelling index was
swelling index was increase
with rate of hydration.  Lat
gelled layer of tablet into di
al., 2011). 
(a) Effect of hydrophilic po
The percentage swe
K4M, F11-HPMC K15M
were found to increase in th
HPMC
The hydrophilic pol
with water. This is due t
macromolecular chains of 
increased (swelling) due to 
(Ramesha C. Nagarwal et a
shown in Table: 6A, 6B & 
(b) Effect of hydrophilic an
The percentage swe
F7-F9 (HPMC K4M & EC
containing the combination
increase in the following ord
                        RESULTS & DISCUS
ERY SYSTEM 
 calculated with respect to time.  As tim
d, because weight gain by tablet was increas
er on, it decreased gradually due to dissolu
ssolution medium (Margret Chandira et al., 2
lymers on swelling index: 
lling index of formulations (F1-HPMC K1
 and F16-Methylcellulose) containing hydr
e following order. 
 K100M > HPMC K15M > HPMC K4M >
ymers formed a gel layer around the tablet w
o the penetration of solvent into the free
polymer and so the dimension of the polym
polymer relaxation caused by stress of the p
l.,   2010 ; Mina Ibrahim Tadros et al., 2010
Figure: 8. 
d hydrophobic polymers on swelling index:
lling index of formulations (F2-F5 (HPMC
): F12-F15 (HPMC K15M & EC): F17
 of hydrophilic and hydrophobic polymer
er. 
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e increases, the 
ed proportionally 
tion of outermost 
010; Amit Jain et 
00M, F6-HPMC 
ophilic polymers 
 MC 
hen they contact 
 spaces between 
er molecule was 
enetrated solvent 
). The results were 
 
 K100M & EC):            
-F20 (MC & EC) 
s were found to 
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HPMC K100M & EC 
It was observed tha
hydrophobic polymers havi
hydrophilic polymers alone
hydrophobic polymer, whic
al., 2011). The results were 
Among all the twen
maximum swelling index o
water retention property of
influence on swelling proce
linear relationship between 
et al., 2010; Deshbhratar R.
5. IN VITRO RELEASE S
The invitro dissolut
studies were performed in 
15minutes interval for the 
absorbance was measured a
(a) Effect of hydrophilic po
The invitro releas
F6-HPMC K4M (80%), 
containing hydrophilic poly
in 12hours respectively. 
                        RESULTS & DISCUS
ERY SYSTEM 
> HPMC K15M & EC > HPMC K4M & EC
t, the tablets containing combination of both
ng less swelling index than that of the formu
.  This could be due to the less permeabilit
h minimized the swelling of the matrix tabl
shown in Table: 6A, 6B & Figure: 8. 
ty formulations, F1(HPMC K100M) formul
f 81.5% at the end of 12hours, due to high v
 HPMC K100M. The viscosity of the poly
ss and matrix integrity. It was concluded th
swelling process and polymer viscosity (Ma
 M. et al., 2010; Praveen Kumar Mandapalli 
TUDIES: 
 
ion studies were carried out by USP type 
all the formulations for 12hours. The samp
first 1hour and 30minutes interval for the n
t 204nm by UV spectrophotometer. 
lymers on invitro drug release studies: 
e studies of formulations (F1-HPMC 
F11-HPMC K15M (80%) & F16-Methy
mers showed drug release at 75.3%, 85.6%,
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 > MC & EC 
 hydrophilic and 
lations containing 
y of water into the 
ets (Doddayya et 
ation showed the 
iscosity and high 
mer had a major 
at, there exists a 
rgret Chandira R 
et al., 2012). 
II method.  The 
les were taken at 
ext 11hours. The 
K100M (80%),                           
lcellulose (75%) 
 80.6%, & 90.3% 
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The drug rele
HPMC
From the above resu
other formulations F6, F11
(HPMC K100M) than the
strong viscous gel layer wh
down the rate of diffusion o
or decrease the drug release
2010; Amit Kumar Nayak 
were shown in  Table: 7A, 7
(b) Effect of hydrophilic an
To increase the relea
a combination of both hydro
In vitro release s
hydrophilic and hydrophobi
& Figure: 10, 11, 12 & 13
The cumulative % 
75% & EC 5%); F7 (HPMC
F17 (MC 70% & EC 5%) 
The cumulative % 
70% & EC 10%); F8 (HP
                        RESULTS & DISCUS
ERY SYSTEM 
ase retarded in the following order, 
 K100M > HPMC K15M > HPMC K4M >
lts, the formulation F1 showed more retarda
, F16.  This was due to the high viscosit
 others. The high viscosity grades induce
en they come in contact with the aqueous m
f medium into the tablet, which may results 
. (Anilkumar J. Shinde et al., 2010; Margret 
 et al., 2011; Ramesh C. Nagarwal et al., 2
B, 7C, 7D & Figure: 9. 
d hydrophobic polymers on invitro drug rel
se retardation of the drug, the formulations 
philic and hydrophobic polymers. 
tudies of formulations containing comb
c polymers. The results were shown in Table
.   
drug release of formulations containing F2
 K4M 75% & EC 5%); F12 (HPMC K15M
showed 74.5%, 84%, 79.6%, & 89.7% in 12 ho
drug release of formulations containing F3
MC K4M 70% & EC 10%); F13 (HPMC
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 MC 
nt effect than the 
y of the polymer 
 the formation of 
edia that slowed 
in the retardation 
Chandira R et al., 
010). The results 
ease studies: 
were prepared by 
ination of both 
: 7A, 7B, 7C, 7D 
 (HPMC K100M 
 75% & EC 5%);                    
urs respectively. 
 (HPMC K100M 
 K15M 70% &          
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EC 10%);  F18 (MC 65% &
respectively. 
The cumulative % 
65% & EC 15%); F9 (HPM
15%);  F19 (MC 60% & E
respectively. 
The cumulative % 
60% & EC 20%); F10 (HP
20%); F20 (MC 55% & EC
respectively. 
The drug rele
HPMC K100M & EC 
From the above res
formulations containing F2
concentration of hydrophi
polymer. Ethyl cellulose 
dissolution medium inside t
the matrix. So that, the dru
to the hydrophilic polymer
prepared with combination
controlled drug release tha
Jain et al., 2011; Deshbhrata
                        RESULTS & DISCUS
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 EC 10%) showed 73.3%, 83.6%, 78.6%, &
drug release of formulations containing F4
C K4M 65% & EC 15%); F14 (HPMC K
C 15%) showed 71.3%, 82.5%, 77.7%, & 8
drug release of formulations containing F5
MC K4M 60% & EC 20%); F15 (HPMC K
 20%) showed 67.1%, 81.3%, 76.6%, & 8
ase retarded in the following order, 
> HPMC K15M & EC > HPMC K4M & EC
ults, it was observed that the drug release
 – F5, F7 – F10, F12 – F15, F17 – F20 due
lic polymer and increased concentration 
is hydrophobic in nature, which restricts 
he matrix and also restricts the formation of
g release from the hydrophobic matrix decre
s. Hence, it was concluded that the floati
 of hydrophilic and hydrophobic polyme
n those prepared using hydrophilic polymer
r R. M et al., 2010). 
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 88% in 12 hours 
 (HPMC K100M 
15M 65% & EC 
7.8% in 12 hours 
 (HPMC K100M 
15M 60% & EC 
6.7% in 12 hours 
 > MC & EC 
 was slower for 
 to the decreased 
of hydrophobic 
the penetration of 
 gel layer around 
ased as compared 
ng matrix tablets 
r showed better 
s alone (Amit K. 
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Among all the twen
selected as a best formulatio
6. INVITRO DRUG RELE
To analyze the relea
studies, the invitro release
models (zero order, first o
release kinetic data for al
Figure: 14. 
The kinetic studies o
linear as indicated by their 
drug release from all th
coefficient values (R
2
) betw
Further F5 formulation show
Diffusion is related 
study fluid depending on th
by Higuchi’s model.  The r
expressed by Higuchi’s equ
high linearity with regressio
The kinetic data of 
which showed the combine
drug release.  By using Kor
controlled drug release (Min
controlled drug release, if 
                        RESULTS & DISCUS
ERY SYSTEM 
ty formulations, F5 (HPMC K100M 60%
n which had the better retardant effect (67.1%
ASE KINETICS STUDIES: 
 
se mechanism as well as to select the formu
 data were fitted into various release equa
rder, Higuchi, Hixson-Crowell, Korsemey
l the formulations were shown in the Ta
f all the formulations showed that zero orde
high regression values.  Therefore it was as
e formulations followed zero order kine
een 0.959 – 0.993) (Praveen Kumar Mandap
ed the closest linearity to unity (R
2 
=0.993)
to the transport of drug from the dosage for
e concentration (Ravikumar et al., 2009). Th
elease profiles of drug from all the formulati
ations (Amit Kumar Nayak et al., 2011), 
n coefficient values (R
2
) between 0.949 – 0.9
all the formulations showed good fit in Ko
d effect of diffusion and erosion mechanis
smeyer-peppas model, if n= 0.45 it indicates
a Ibrahim Tadros et al., 2010), if n=0.89 it i
n values between 0.45 to 0.89 can be regarde
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 & EC 20%) was 
 in 12 hours).  
lation for in vivo 
tions and kinetic 
er-Peppas).  The 
ble: 8A &8B &      
r plots were fairly 
certained that the 
tics (Regression 
alli et al., 2012). 
.  
m into the invitro 
is was explained 
ons could be best 
as the plot showed 
92. 
rsmeyer equation 
m for controlled 
 Fickian diffusion 
ndicates swelling 
d as an indicator 
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for both the phenomena (A
Nagarwal et al., 2010; Ami
clear that all formulations 
transport (Both diffusion an
It was found that t
Fickian diffusion (the relea
when added to water and b
rearrangement of macromol
V. SELECTION OF BEST
From above the results o
 Invitro Release Prof
 Invitro Release Kine
 
 Floating Lag Time   
A) EVALUATION OF BE
            The selected of best 
1. Comparison with 
2. Assay by HPLC m
3. Scanning Electron
4. In vivo x-ray stud
5. Stability studies 
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nomalous transport or Non-Fickian diffus
t Kumar Nayak et al., 2011; Praveen Kumar 
have ‘n’ values between 0.45 to 0.89, indic
d erosion). 
he mechanism for all formulations were
se from initially dry, hydrophilic glassy po
ecome rubbery show anomalous diffusion 
ecular chains) (Sasa Baumgartner et al., 2000
 FORMULATION: 
f characterization F5 was selected the best f
ile    67.1% in 12hours 
tics    Zero Order Kinetics (Closes
  R
2 =
0.993) 
    Floats Immediately 
ST FORMULATION 
formulation were subjected to, 
marketed formulation 
ethod 
 Microscopy 
ies 
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ion) (Ramesh C. 
et al., 2011).  It’s 
ating Anomalous 
 Anomalous Non-
lymers that swell 
as a result of the 
). 
ormulation. 
t Linearity          
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1. COMPARISON WITH
The promising form
with marketed product (Co
release of the best formulat
marketed product whose c
formulation F5 showed con
The results were shown in 
2. ASSAY BY HPLC MET
     The percentage o
by high performance liqu
100.573% (40.229mg of V
formulation complies with o
same result was obtained b
The results were shown in 
3. SCANNING ELECTRO
        The surface topograp
formulation were evaluated
before and after dissolution
any perforations, channels o
and moves slowly toward th
it comes in contact with 
showed a network in the 
surrounding medium. Henc
                        RESULTS & DISCUS
ERY SYSTEM 
 MARKETED FORMULATION 
ulation (F5) as found by evaluation studie
nventional Tablet - Valent 40mg).  The cu
ion was found to be 67.1% in 12hours when
umulative % drug release was 101% in 
trolled release profile than the marketed co
Figure: 15. 
HOD 
f valsartan content from the best formulatio
id chromatography (HPLC) method and w
alsartan). Hence, the percentage drug con
fficial specifications as per U.S.P (Limits:
y UV spectrometry while analyze the best 
Figure: 16A, 16B & 17. 
N MICROSCOPY 
hy, texture and morphology of fractured
 by using SEM.  The SEM images of the t
. The SEM images of the tablet showed intac
r troughs. After dissolution the solvent front
e centre of the tablet. The drug diffuses out o
dissolution medium.  The SEM images of
swollen polymer through which the drug
e, it was concluded that the drug was release
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s was compared 
mulative % drug 
 compared to the 
1hour. Thus the 
nventional tablet.  
n was determined 
as found to be 
tent of the best 
 90% - 110%). The 
formulation (F5). 
 surface of best 
ablets were taken 
t surface without 
 enters the matrix 
f the matrix after 
 the formulation 
 diffused to the 
d from  matrix by 
CHAPTER XI             
 
FLOATING DRUG DELIV
 
diffusion mechanism (Man
Figure: 18.   
4. IN VIVO X-RAY STUD
        The in vivo X-ray stud
Animal Ethical Committee
were conducted to find out 
formulation developed by u
was monitored by taking x
x-ray machine. The tablet w
part of stomach confirmed i
be visualized from the inc
4
th
 hour, 8
th
 hour, 10
th
 hou
than 12 hours.  Hence, it w
gastric region to ensure co
Figure: 19. 
5. STABILITY STUDIES
Optimized formulat
The results showed no sign
during storage. Thus it wa
were stable under these stor
                        RESULTS & DISCUS
ERY SYSTEM 
oj N. Gambhire et al., 2007).  The result
IES 
ies were carried out after getting clearance 
 and are performed on healthy albino rabb
the gastric retention of tablet.  After adminis
sing barium sulphate, the duration of the tab
-rays at periodic time intervals (0, 2, 4, 6, 8
as clearly seen in the GIT at different posit
ts in vivo floating behavior. Also the swelling
rease in the size of tablets in the images t
r & 12
th
 hour.  Gastric residence time was f
as concluded that the formulation could b
mplete drug release. The x-ray photograph
 
ion F5 was subjected to stability studies at
ificant change in the physical appearance 
s found that the gastro retentive floating ta
age conditions. The results were shown in th
SION   
Page 129 
s were shown in 
from Institutional 
it. X-ray studies 
tration of the best 
let in the stomach 
, 10, & 12) using    
ions on the upper 
 of the tablet can 
aken at 2
nd
 hour,       
ound to be more 
e retained in the 
s were shown in 
 40°C at 75% RH. 
and drug content 
blets of valsartan 
e Table: 9 
CHAPTER XII            
 
FLOATING DRUG DELIV
 
SUM
 Floating drug delive
increased gastric re
essential for sustaine
 The present work w
of valsartan based o
combines advantage
successful in the fiel
 The floating dosag
absorption, by retain
 The λmax of valsartan
 The valsartan obeys 
 DSC & FT-IR stud
excipients. 
 The twenty formul
prepared by non-
polymers. 
 The formulated tab
parameters, invitro
etc. 
 The precompression
limit that was suitab
                    SUMMARY & CONCL
ERY SYSTEM 
CHAPTER XII 
MARY AND CONCLUSION 
 
ry system offers a simple and practical app
sidence time (GRT) and to modify drug
d, site specific and localized drug action. 
as aimed towards developing a floating drug
n novel approaches. It was hypothesized t
s of both floating and sustained release te
d of Novel drug delivery system. 
e form of valsartan has been formulated
ing the drug in stomach for a prolonged perio
 was found to be 204nm in 0.1N hydrochlori
the Beer’s law within the concentration of 2 
ies indicated that there was no interaction b
ations of valsartan floating matrix tablet
effervescent techniques using hydrophilic 
lets were analyzed for precompression &
 release, release kinetics, in vivo x-ray studies
 parameters of all the formulations were w
le for formulation of the tablets. 
USION  
Page 130 
roach to achieve 
 release profiles 
 delivery system 
hat a system that 
chnology can be 
 to improve the 
d of time. 
c acid. 
to 20µg/ml. 
etween drug and 
s (F1-F20) were 
and hydrophobic 
 postcompression 
, stability studies 
ithin the required 
CHAPTER XII            
 
FLOATING DRUG DELIV
 
 The postcompressio
& drug content of al
 The floating lag time
 Polymer swelling w
important for flotati
swelling process and
 Hydrophilic polyme
come in contact with
medium into the tab
release. 
 The combination of
penetration of dissol
gel layer around the
tablets decreased as 
the floating matrix 
hydrophobic polyme
using hydrophilic po
 The in vitro dissolu
of the drug over a
(HPMC K100M 60%
the better retardant e
 All the formulation
diffusion mechanism
                    SUMMARY & CONCL
ERY SYSTEM 
n parameters such as hardness, friability, unif
l the formulated tablets were within the accep
 & duration of buoyancy were found to be sa
as crucial in determining the drug relea
on. The viscosity of the polymer had a m
 matrix integrity. 
rs induce the formation of strong viscous ge
 the aqueous media that slowed down the ra
let, which may results in the retardation or 
 hydrophilic and hydrophobic polymers, w
ution medium inside the matrix, also restrict
 matrix. So that, the drug release from the hy
compared to the hydrophilic polymers. It w
tablets prepared with the combination of bo
r showed better controlled drug release tha
lymers alone. 
tion studies of all the formulations showed 
 period of 12hrs.  Among all the twenty 
 & EC 20%) was selected as a best formu
ffect (67.1% in 12 hours) & subjected to furt
s followed zero order kinetics and Anoma
. 
USION  
Page 131 
ormity in weight, 
table limits. 
tisfied. 
se rate and also 
ajor influence on 
l layer when they 
te of diffusion of 
decrease the drug 
hich restricts the 
s the formation of 
drophobic matrix 
as concluded that 
th hydrophilic & 
n those prepared 
controlled release 
formulations, F5 
lation which had 
her studies. 
lous Non-Fickian 
CHAPTER XII            
 
FLOATING DRUG DELIV
 
 The selected formu
conventional tablet.
 The HPLC analysis
per U.S.P. 
 The SEM images o
perforations, channe
 The in vivo x-ray st
time of more than 12
 The selected formula
CONCLUSION 
The results of the pr
in the form of floating drug
and controlled drug relea
pharmacokinetic parameter
which may prove that this
treatment of hypertension w
                    SUMMARY & CONCL
ERY SYSTEM 
lation showed controlled release profile th
 
 of best formulation complies with official
f the selected formulation showed intact sur
ls or toughs. 
udies showed that the best formulation had
hrs. 
tion was found to be stable under the storage
esent study clearly indicate the feasibility to 
 delivery system with prolongation of gast
se. The future studies may be extende
s related to bioavailability and clinical tri
 type of the formulation can be administer
ith improved therapeutic efficacy. 
USION  
Page 132 
an the marketed 
 specifications as 
face without any 
 gastric retention 
 conditions. 
develop valsartan 
ric retention time 
d to reveal the 
al investigations, 
ed safely for the 
200 220 240 260 280 300 320 340 360 380 400
0.0
0.2
0.4
0.6
0.8
1.0
1.2
WAVELENGTH (nm)
A
B
S
O
R
B
A
N
C
E
 
 
λmax=204nm 
 
FIGURE 1: DETERMINATION OF λmax OF VALSARTAN 
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FIGURE 2: CALIBRATION CURVE OF VALSARTAN IN 0.1N HYDROCHLORIC ACID 
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FIGURE 4: FT-IR SPECTRUM OF DRUG, POLYMERS & PHYSICAL MIXTURE 
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FIGURE 3: DSC THERMOGRAM OF DRUG, POLYMERS & PHYSICAL MIXTURE 
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FIGURE 6: IN VITRO FLOATING BEHAVIOUR OF ALL FORMULATIONS 
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FIGURE 9: IN VITRO RELEASE PROFILE OF VALSARTAN FLOATING MATRIX TABLETS 
CONTAINING HYDROPHILIC POLYMERS 
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FIGURE 10: IN VITRO RELEASE PROFILE OF VALSARTAN FLOATING MATRIX TABLETS 
CONTAINING COMBINATION OF HYDROPHILIC AND HYDROPHOBIC POLYMERS 
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FIGURE 11: IN VITRO RELEASE PROFILE OF VALSARTAN FLOATING MATRIX TABLETS 
CONTAINING COMBINATION OF HYDROPHILIC AND HYDROPHOBIC POLYMERS 
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FIGURE 12: IN VITRO RELEASE PROFILE OF VALSARTAN FLOATING MATRIX TABLETS 
CONTAINING COMBINATION OF HYDROPHILIC AND HYDROPHOBIC POLYMERS 
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FIGURE 13: IN VITRO RELEASE PROFILE OF VALSARTAN FLOATING MATRIX TABLETS 
CONTAINING COMBINATION OF HYDROPHILIC AND HYDROPHOBIC POLYMERS 
 COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS 
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 2 4 6 8 10 12 14
0
20
40
60
80
100
F1 HPMCK100M (80%) F6 HPMCK4M (80%)
F11 HPMCK15M (80%) F16 MC (75%)
 
COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS 
TIME IN HOURS
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 2 4 6 8 10 12 14
0.0
0.5
1.0
1.5
2.0
2.5
F1 HPMCK100M (80%) F6 HPMCK4M (80%)
F11 HPMCK15M (80%) F16 MC (75%)
 
 
COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS 
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 1 2 3 4
0
20
40
60
80
100
F1 HPMCK100M (80%) F6 HPMCK4M (80%)
F11 HPMCK15M (80%) F16 MC (75%)
 
 
COMPARISON OF INVITRO HIXSON CROWELL MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS 
TIME IN HOURS
C
U
B
I
C
 
R
O
O
T
 
O
F
 
C
U
M
U
L
A
T
I
V
E
%
 
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 5 10 15
0
1
2
3
4
5
F1 HPMCK100M (80%) F6 HPMCK4M (80%)
F11 HPMCK15M (80%) F16 MC (75%)
 
COMPARISON OF INVITRO KORSEMEYER PEPPAS MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS 
LOG TIME
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
F1 HPMCK100M (80%) F6 HPMCK4M (80%)
F11 HPMCK15M (80%) F16 MC (75%)
 
 
COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 2 4 6 8 10 12 14
0
20
40
60
80
100
F2 HPMCK100M 75% + EC 5% F7 HPMCK4M 75% + EC 5%
F12 HPMCK15M 75% + EC 5% F17 MC 70% + EC 5%
 
COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 2 4 6 8 10 12 14
0.0
0.5
1.0
1.5
2.0
2.5
F2 HPMCK100M 75% + EC 5% F7 HPMCK4M 75% + EC 5%
F12 HPMCK15M 75% + EC 5% F17 MC 70% + EC 5%
 
COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 1 2 3 4
0
20
40
60
80
100
F2 HPMCK100M 75% + EC 5% F7 HPMCK4M 75% + EC 5%
F12 HPMCK15M 75% + EC 5% F17 MC 70% + EC 5%
 
COMPARISON OF INVITRO HIXSON CROWELL MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
C
U
B
I
C
 
R
O
O
T
 
O
F
 
C
U
M
U
L
A
T
I
V
E
%
 
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 5 10 15
0
1
2
3
4
5
F2 HPMCK100M 75% + EC 5% F7 HPMCK4M 75% + EC 5%
F12 HPMCK15M 75% + EC 5% F17 MC 70% + EC 5%
 
COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS 
& HYDROPHOBIC POLYMERS 
LOG TIME
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
F2 HPMCK100M 75% + EC 5% F7 HPMCK4M 75% + EC 5%
F12 HPMCK15M 75% + EC 5% F17 MC 70% + EC 5%
 
COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 2 4 6 8 10 12 14
0
20
40
60
80
100
F3 HPMCK100M 70% + EC 10% F8 HPMCK4M 70% + EC 10%
F13 HPMCK15M 70% + EC 10% F18 MC 65% + EC 10%
 
 
COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 2 4 6 8 10 12 14
0.0
0.5
1.0
1.5
2.0
2.5
F3 HPMCK100M 70% + EC 10% F8 HPMCK4M 70% + EC 10%
F13 HPMCK15M 70% + EC 10% F18 MC 65% + EC 10%
 
COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 1 2 3 4
0
20
40
60
80
100
F3 HPMCK100M 70% + EC 10% F8 HPMCK4M 70% + EC 10%
F13 HPMCK15M 70% + EC 10% F18 MC 65% + EC 10%
 
COMPARISON OF INVITRO HIXSON CROWELL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
C
U
B
I
C
 
R
O
O
T
 
O
F
 
C
U
M
U
L
A
T
I
V
E
%
 
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 5 10 15
0
1
2
3
4
5
F3 HPMCK100M 70% + EC 10% F8 HPMCK4M 70% + EC 10%
F13 HPMCK15M 70% + EC 10% F18 MC 70% + EC 10%
 
COMPARISON OF INVITRO KORSMEYER PEPPAS MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS 
& HYDROPHOBIC POLYMERS 
LOG TIME
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
F3 HPMCK100M 70% + EC 10% F8 HPMCK4M 70% + EC 10%
F13 HPMCK15M 70% + EC 10% F18 MC 65% + EC 10%
 
COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 2 4 6 8 10 12 14
0
20
40
60
80
100
F4 HPMCK100M 65% + EC 15% F9 HPMCK4M 65% + EC 15%
F14 HPMCK15M 65% + EC 15% F19 MC 60% + EC 15%
 
COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
TIME IN HOURS
L
O
G
 
C
U
M
U
L
A
T
I
V
E
 
%
D
R
U
G
 
R
E
M
A
I
N
I
N
G
0 2 4 6 8 10 12 14
0.0
0.5
1.0
1.5
2.0
2.5
F4 HPMCK100M 65% + EC 15% F9 HPMCK4M 65% + EC 15%
F14 HPMCK15M 65% + EC 15% F19 MC 60% + EC 15%
 
COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
SQUARE ROOT OF TIME
C
U
M
U
L
A
T
I
V
E
 
%
 
D
R
U
G
 
R
E
L
E
A
S
E
0 1 2 3 4
0
20
40
60
80
100
F4 HPMCK100M 65% + EC 15% F9 HPMCK4M 65% + EC 15%
F14 HPMCK15M 65% + EC 15% F19 MC 60% + EC 15%
 
COMPARISON OF INVITRO HIXSON CROWELL MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
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COMPARISON OF INVITRO ZERO ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
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COMPARISON OF INVITRO FIRST ORDER RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
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COMPARISON OF INVITRO HIGUCHI MODEL RELEASE KINETICS OF HYDROPHILIC POLYMERS & 
HYDROPHOBIC POLYMERS 
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FIGURE 14: INVITRO DRUG RELEASE KINETICS 
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FIGURE 15: IN VITRO RELEASE PROFILE OF BEST FORMULATION COMPARED WITH                    
MARKETED PRODUCT 
HPLC CHROMATOGRAM OF VALSARTAN IN THE MOBILE PHASE 
 
 
(A) RETENTION TIME AREA OF STANDARD VALSARTAN 
 
 
 
 (B) RETENTION TIME AREA OF SAMPLE VALSARTAN (BEST FORMULATION) 
 
 
FIGURE 16: (A) RETENTION TIME AREA OF STANDARD VALSARTAN,                                        
(B) RETENTION TIME AREA OF SAMPLE VALSARTAN (BEST FORMULATION) 
  
 
 
 
 
FIGURE 17: COMPARISON OF DRUG CONTENT OF VALSARTAN FLOATING MATRIX TABLET                  
(BEST FORMULATION) BY UV AND HPLC METHOD 
       
    BEFORE        AFTER 
 
 
 
FIGURE 18: SCANNING ELECTRON MICROSCOPY IMAGES OF TABLET SURFACES (BEST 
FORMULATION) BEFORE AND AFTER DISSOLUTION 
                
           0 HOUR             2nd HOUR        4thHOUR     6th HOUR 
           
                      8th HOUR             10th HOUR                         12th HOUR 
 
FIGURE 19 : IN VIVO X-RAY PHOTOGRAPHS OF VALSARTAN FLOATING MATRIX TABLET                        
(BEST FORMULATION) 
 TABLE: 1- CALIBRATION OF VALSARTAN IN 0.1N HYDROCHLORIC ACID 
S.No. CONCENTRATION (µg/ml) ABSORBANCE ± SD* 
1. 2 0.188 ± 0.006 
2. 4 0.386 ± 0.008 
3. 6 0.593 ± 0.004 
4. 8 0.771 ± 0.014 
5. 10 0.953 ± 0.013 
6. 12 1.124 ± 0.011 
7. 14 1.319 ± 0.016 
8. 16 1.495 ± 0.022 
9. 18 1.704 ± 0.017 
10. 20 1.893 ± 0.018 
                                         n = 3*                                                                                          γ = 0.99980  
 TABLE: 2A- COMPOSITION OF VALSARTAN FLOATING MATRIX TABLETS (F1 – F10) 
 
S.NO 
 
INGREDIENTS 
 
QUANTITY FOR 1 TABLET (mg) 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
F10 
1. Valsartan 40 40 40 40 40 40 40 40 40 40 
2. HPMC K100M 200 187.5 175 162.5 150 - - - - - 
3. HPMC K4M - - - - - 200 187.5 175 162.5 150 
4. HPMC K15M - - - - - - - - - - 
5. Methylcellulose - - - - - - - - - - 
6. Ethyl cellulose - 12.5 25 37.5 50 - 12.5 25 37.5 50 
7. Lactose 5 5 5 5 5 5 5 5 5 5 
8. Talc (1%) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
9. Magnesium Stearate (1%) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
 
Total Weight 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
 TABLE: 2B- COMPOSITION OF VALSARTAN FLOATING MATRIX TABLETS (F11 – F20) 
 
S.NO 
 
INGREDIENTS 
 
QUANTITY FOR 1 TABLET (mg) 
 
F11 
 
F12 
 
F13 
 
F14 
 
F15 
 
F16 
 
F17 
 
F18 
 
F19 
 
F20 
1. Valsartan 40 40 40 40 40 40 40 40 40 40 
2. HPMC K100M - - - - - - - - - - 
3. HPMC K4M - - - - - - - - - - 
4. HPMC K15M 200 187.5 175 162.5 150 - - - - - 
5. Methylcellulose - - - - - 187.5 175 162.5 150 137.5 
6. Ethyl cellulose - 12.5 25 37.5 50 - 12.5 25 37.5 50 
7. Lactose 5 5 5 5 5 17.5 17.5 17.5 17.5 17.5 
8. Talc (1%) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
9. Magnesium Stearate (1%) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
 
Total Weight 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
TABLE: 3A- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND (F1 – F10) 
 
FORMULATION 
CODE 
 
ANGLE OF 
REPOSE (θ) * 
 
BULK 
DENSITY 
(g/ml) * 
 
TAPPED 
DENSITY 
(g/ml) * 
 
COMPRESSIBILITY 
INDEX (%)* 
 
HAUSNER’S 
RATIO* 
 
% DRUG 
CONTENT * 
F1 30º.13’ 0.312 0.367 14.98 1.17 99.68 
F2 29º.19’ 0.297 0.390 23.8 1.21 99.79 
F3 28º.17’ 0.265 0.320 17.03 1.20 99.47 
F4 29º.93’ 0.290 0.390 25.0 1.24 99.37 
F5 28º.09’ 0.297 0.378 21.42 1.25 99.58 
F6 28º.60’ 0.277 0.367 24.46 1.22 99.58 
F7 28º.53’ 0.250 0.290 14 1.16 99.68 
F8 28º.15’ 0.265 0.357 24.9 1.24 99.26 
F9 28º.03’ 0.255 0.337 24.48 1.22 99.16 
F10 27º.99’ 0.347 0.446 22.19 1.18 99.16 
n=3* 
 
TABLE: 3B- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND (F11 – F20) 
 
FORMULATION 
CODE 
 
ANGLE OF 
REPOSE (θ) * 
 
BULK 
DENSITY 
(g/ml) * 
 
TAPPED 
DENSITY 
(g/ml) * 
 
COMPRESSIBILITY 
INDEX (%)* 
 
HAUSNER’S 
RATIO* 
 
% DRUG 
CONTENT * 
F11 27º.08’ 0.357 0.480 25.03 1.24 99.26 
F12 29º.53’ 0.367 0.480 23.5 1.20 99.26 
F13 28º.24’ 0.357 0.462 22.7 1.24 99.16 
F14 29º.54’ 0.312 0.416 24.98 1.20 99.16 
F15 30º.26’ 0.320 0.416 23.06 1.19 99.05 
F16 28º.50’ 0.297 0.357 16 1.19 98.95 
F17 28º.34’ 0.296 0.416 20.6 1.20 98.84 
F18 28º.35’ 0.284 0.357 20.4 1.25 98.63 
F19 28º.17’ 0.337 0.415 18.9 1.23 98.68 
F20 28º.24’ 0.271 0.357 23.91 1.21 98.32 
n=3* 
 
TABLE: 4A- POSTCOMPRESSIONAL EVALUATION OF VALSARTAN FLOATING MATRIX TABLETS (F1 – F10) 
FORMULATION 
CODE 
GENERAL 
APPEARANCE 
HARDNESS 
(kg/cm
2
)* 
THICKNESS 
(mm)* 
DIAMETER 
(mm)* 
FRIABILITY 
(%)* 
WEIGHT 
VARIATION 
(mg)* 
% DRUG 
CONTENT * 
F1 
White color, 
biconvex  shaped 
3 4 10 0.13 249.54 99.79 
F2 
White color, 
biconvex shaped 
4 4 10 0.25 249.17 99.58 
F3 
White color, 
biconvex shaped 
4 4 10 0.27 248.09 99.37 
F4 
White color, 
biconvex shaped 
4 4 10 0.22 247.00 99.47 
F5 
White color, 
biconvex shaped 
4 4 10 0.28 249.03 99.79 
F6 
White color, 
biconvex shaped 
4 3.9 10 0.23 246.91 99.47 
F7 
White color, 
biconvex shaped 
4 3.9 10 0.38 247.64 99.47 
F8 
White color, 
biconvex shaped 
4 3.9 10 0.21 247.80 99.37 
F9 
White color, 
biconvex shaped 
4 3.9 10 0.36 246.71 99.79 
F10 
White color, 
biconvex  shaped 
4 3.9 10 0.30 244.25 99.58 
n=3* 
TABLE: 4B- POSTCOMPRESSIONAL EVALUATION OF VALSARTAN FLOATING MATRIX TABLETS                     
(F11 – F20) 
FORMULATION 
CODE 
GENERAL 
APPEARANCE 
HARDNESS 
(kg/cm
2
)* 
THICKNESS 
(mm)* 
DIAMETER 
(mm)* 
FRIABILITY 
(%)* 
WEIGHT 
VARIATION 
(mg)* 
% DRUG 
CONTENT * 
F11 
White color, 
biconvex shaped 
4 3.9 10 0.27 247.99 99.79 
F12 
White color, 
biconvex shaped 
4 3.9 10 0.35 247.76 99.89 
F13 
White color, 
biconvex shaped 
3.5 3.9 10 0.43 246.50 99.58 
F14 
White color, 
biconvex shaped 
4 3.9 10 0.28 246.58 99.37 
F15 
White color, 
biconvex shaped 
4 3.9 10 0.23 247.54 99.37 
F16 
White color, 
biconvex shaped 
3 3.5 10 0.32 245.64 99.27 
F17 
White color, 
biconvex shaped 
3.5 3.5 10 0.29 247.73 99.35 
F18 
White color, 
biconvex shaped 
3.5 3.9 10 0.50 248.18 99.79 
F19 
White color, 
biconvex shaped 
4 3.9 10 0.25 248.74 99.16 
F20 
White color, 
biconvex shaped 
3.5 3.9 10 0.30 248.08 98.63 
n=3* 
TABLE: 5A- IN VITRO BUOYANCY LAG TIME AND TOTAL FLOATING TIME OF VALSARTAN FLOATING 
MATRIX TABLETS (F1 – F10) 
 
FORMULATION CODE 
 
BUOYANCY LAG TIME * 
 
TOTAL FLOATING TIME (hrs) * 
F1 FLOATS IMMEDIATELY >24hrs 
F2 FLOATS IMMEDIATELY >24hrs 
F3 FLOATS IMMEDIATELY >24hrs 
F4 FLOATS IMMEDIATELY >24hrs 
F5 FLOATS IMMEDIATELY >24hrs 
F6 FLOATS IMMEDIATELY >24hrs 
F7 FLOATS IMMEDIATELY >24hrs 
F8 FLOATS IMMEDIATELY >24hrs 
F9 FLOATS IMMEDIATELY >24hrs 
F10 FLOATS IMMEDIATELY >24hrs 
n=3* 
TABLE: 5B- IN VITRO BUOYANCY LAG TIME AND TOTAL FLOATING TIME OF VALSARTAN FLOATING 
MATRIX TABLETS (F11 – F20) 
 
FORMULATION CODE 
 
BUOYANCY LAG TIME * 
 
TOTAL FLOATING TIME (hrs) * 
F11 FLOATS IMMEDIATELY >24hrs 
F12 FLOATS IMMEDIATELY >24hrs 
F13 FLOATS IMMEDIATELY >24hrs 
F14 FLOATS IMMEDIATELY >24hrs 
F15 FLOATS IMMEDIATELY >24hrs 
F16 10 Minutes >24hrs 
F17 3 Minutes 20 Seconds >24hrs 
F18 10 Minutes 15 Seconds >24hrs 
F19 15 Minutes >24hrs 
F20 8 Minutes 10 Seconds >24hrs 
n=3* 
 
TABLE: 6A- IN VITRO SWELLING INDEX OF VALSARTAN FLOATING MATRIX TABLETS (F1 – F10) 
 
 
 
FORMULATION   
CODE 
 
% SWELLING INDEX 
 
TIME IN HOURS 
2 4 6 8 10 12 
F1 63.9 72.3 77.1 79.2 81.5 81.5 
F2 63.7 71.9 75.8 78.6 79.9 80.2 
F3 59.3 68.7 74 77 79.4 80.2 
F4 59.9 69.6 74.3 76.7 79.6 76.0 
F5 58.2 67.9 73.1 73.9 76.8 75.7 
F6 59.2 67.9 71.3 73.8 75.1 74.0 
F7 54.8 61.9 67.2 68.8 70.7 68.7 
F8 53.3 62.1 67.7 66.9 69.6 67.7 
F9 54.7 63.3 67.2 67.3 67.2 65.7 
F10 59.6 65.6 71.4 72.2 74.1 64.5 
TABLE: 6B- IN VITRO SWELLING INDEX OF VALSARTAN FLOATING MATRIX TABLETS (F11 – F20) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FORMULATION   
CODE 
 
% SWELLING INDEX 
 
TIME IN HOURS 
2 4 6 8 10 12 
F11 64.8 69.8 73.1 74.7 75.3 75.0 
F12 61.9 66.1 71.9 74.4 75 74.4 
F13 59.4 69.9 70.3 72.6 73.3 74.6 
F14 56.2 67.1 70.0 70.7 73.6 73.4 
F15 53.1 63.4 67.9 70.2 68.3 66.1 
F16 57.3 64.4 69.5 71.9 73.3 70.1 
F17 56.1 63.0 67.2 67.9 70.8 67.8 
F18 53.2 63.0 66.7 66.9 70.0 66.7 
F19 53.7 60.7 63.9 67.6 67.2 64.8 
F20 52.6 61.1 65.1 68.6 68.0 64.0 
 TABLE: 7A- IN VITRO RELEASE DATA OF VALSARTAN FLOATING MATRIX TABLETS (F1 – F5) 
 
TIME IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* (n=3*) 
F1 (HPMC 
K100M 80%) 
F2 (HPMC 
K100M 75% + 
EC 5%) 
F3 (HPMC 
K100M 70% + 
EC 10%) 
F4 (HPMC 
K100M 65% + 
EC 15%) 
F5 (HPMC 
K100M 60% + 
EC 20%) 
0.25 21.2 ± 0.29 22.0 ± 0.57 19.7 ± 0.47 21.5 ± 0.36 17.8 ± 0.29 
0.50 22.5 ± 0.57 24.1 ± 0.49 22.0 ± 1.86 23.5 ± 0.57 19.4 ± 0.18 
0.75 24.5 ± 0.75 26.7 ± 0.20 26.1 ± 0.49 25.6 ± 0.47 21.0 ± 0.93 
1.0 26.9 ± 0.45 29.3 ± 0.16 27.9 ± 0.57 27.1 ± 0.38 23.3 ± 0.30 
1.5 29.7 ± 0.53 33.2 ± 0.20 29.8 ± 0.40 28.7 ± 0.16 25.1 ± 0.67 
2.0 32.6 ± 0.32 34.7 ± 0.36 31.5 ± 0.36 29.9 ± 0.20 27.5 ± 0.38 
2.5 34.9 ± 0.29 36.1 ± 0.24 33.4 ± 0.28 31.2 ± 0.28 29.2 ± 0.24 
3.0 36.8 ± 0.08 37.8 ± 0.14 35.4 ± 0.56 34.1 ± 0.36 30.2 ± 0.45 
3.5 38.4 ± 0.30 38.6 ± 0.09 36.9 ± 0.56 35.2 ± 0.16 31.6 ± 0.44 
4.0 41.8 ± 0.20 41.4 ± 0.29 38.8 ± 0.78 38.1 ± 1.14 33.2 ± 0.57 
4.5 43.5 ± 0.43 42.7 ± 0.30 40.7 ± 0.87 39.5 ± 1.03 34.9 ± 0.16 
5.0 44.7 ± 0.21 44.0 ± 0.09 42.9 ± 0.41 39.7 ± 2.06 36.6 ± 0.18 
5.5 45.8 ± 0.14 45.1 ± 0.21 44.6 ± 0.46 42.1 ± 0.77 38.4 ± 0.21 
6.0 48.0 ± 0.29 46.7 ± 0.29 46.6 ± 0.30 43.6 ± 0.74 40.1 ± 0.23 
6.5 49.6 ± 0.28 48.6 ± 0.20 48.3 ± 0.12 44.9 ± 0.61 42.2 ± 0.36 
7.0 52.2 ± 0.14 52.5 ± 0.16 50.4 ± 0.37 46.2 ± 0.12 44.0 ± 0.47 
7.5 54.3 ± 0.24 54.4 ± 0.57 52.4 ± 0.28 47.7 ± 0.16 45.9 ± 0.29 
8.0 57.7 ± 0.43 57.9 ± 1.88 54.8 ± 0.58 49.4 ± 0.14 47.7 ± 0.23 
8.5 59.8 ± 0.44 61.3 ± 0.37 56.6 ± 0.65 50.9 ± 0.20 49.3 ± 0.12 
9.0 61.4 ± 0.26 62.1 ± 0.20 58.7 ± 0.55 55.7 ± 1.22 50.9 ± 0.23 
9.5 63.6 ± 0.20 64.3 ± 0.40 60.4 ± 0.77 56.9 ± 0.41 54.1 ± 0.78 
10.0 65.7 ± 0.24 65.4 ± 0.30 63.2 ± 0.72 59.2 ± 0.53 56.5 ± 0.36 
10.5 67.8 ± 0.44 67.3 ± 0.36 65.6 ± 1.39 62.9 ± 1.42 59.3 ± 0.29 
11.0 70.4 ± 0.08 70.6 ± 0.16 68.8 ± 1.94 63.6 ± 0.82 61.5 ± 0.24 
11.5 71.9 ± 0.44 72.6 ± 0.14 70.8 ± 1.79 68.0 ± 0.30 63.6 ± 0.29 
12.0 75.3 ± 0.16 74.5 ± 0.36 73.3 ± 0.70 71.3 ± 0.53 67.1 ± 0.80 
 TABLE: 7B- IN VITRO RELEASE DATA OF VALSARTAN FLOATING MATRIX TABLETS (F6 – F10) 
 
TIME IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* (n=3*) 
F6 (HPMC 
K4M 80%) 
F7 (HPMC 
K4M 75% + 
EC 5%) 
F8 (HPMC 
K4M 70% + 
EC 10%) 
F9 (HPMC 
K4M 65% + 
EC 15%) 
F10 (HPMC 
K4M 60% + 
EC 20%) 
0.25 22.8 ± 0.57 21.5 ± 0.45 16.1 ± 0.47 18.4 ± 0.16 21.5 ± 0.20 
0.50 24.4 ± 0.94 23.3 ± 0.56 18.2 ± 1.12 19.9 ± 0.47 24.0 ± 0.67 
0.75 26.4 ± 1.18 25.9 ± 0.73 20.3 ± 1.90 21.7 ± 0.47 25.5 ± 0.61 
1.0 28.6 ± 1.10 28.1 ± 0.45 23.3 ± 1.99 25.3 ± 1.85 27.4 ± 0.52 
1.5 30.7 ± 0.69 30.5 ± 0.35 25.5 ± 2.22 26.5 ± 1.76 30.0 ± 0.87 
2.0 33.2 ± 0.49 32.5 ± 0.12 27.8 ± 2.20 28.6 ± 1.80 31.6 ± 1.25 
2.5 35.1 ± 0.47 34.2 ± 0.12 30.1 ± 2.45 31.5 ± 2.97 33.3 ± 1.12 
3.0 37.1 ± 1.08 36.2 ± 0.47 32.0 ± 3.22 33.4 ± 2.73 34.8 ± 0.80 
3.5 39.5 ± 1.13 38.9 ± 0.20 33.8 ± 3.30 35.7 ± 3.23 37.0 ± 1.18 
4.0 42.0 ± 1.63 42.0 ± 0.57 36.7 ± 3.42 38.6 ± 3.26 40.2 ± 1.13 
4.5 44.7 ± 2.36 44.0 ± 0.93 38.6 ± 3.47 40.8 ± 3.30 42.5 ± 1.06 
5.0 47.4 ± 2.36 46.1 ± 1.02 40.6 ± 3.80 43.7 ± 4.00 45.2 ± 1.57 
5.5 50.6 ± 2.61 48.8 ± 1.75 43.2 ± 3.31 44.9 ± 3.94 48.0 ± 1.72 
6.0 53.3 ± 2.49 51.5 ± 1.81 46.4 ± 3.24 47.8 ± 3.63 50.6 ± 2.20 
6.5 55.7 ± 2.73 55.0 ± 0.84 49.3 ± 3.46 51.4 ± 4.51 53.1 ± 2.12 
7.0 58.0 ± 2.88 57.4 ± 1.43 52.3 ± 3.16 53.9 ± 3.63 55.9 ± 2.66 
7.5 60.3 ± 2.70 60.8 ± 1.40 55.7 ± 3.44 57.4 ± 4.51 59.1 ± 2.68 
8.0 62.9 ± 2.74 63.8 ± 1.15 58.5 ± 3.36 60.2 ± 3.63 61.8 ± 2.05 
8.5 65.9 ± 1.75 66.6 ± 1.21 60.9 ± 3.31 62.2 ± 4.46 64.1 ± 1.98 
9.0 68.3 ± 1.79 69.3 ± 0.86 63.9 ± 3.72 65.5 ± 3.70 67.7 ± 1.73 
9.5 71.0 ± 2.01 71.7 ± 0.62 66.8 ± 3.47 68.3 ± 3.66 70.1 ± 1.03 
10.0 73.4 ± 1.94 74.7 ± 0.08 69.4 ± 2.79 70.2 ± 3.81 72.0 ± 0.96 
10.5 76.8 ± 2.38 77.8 ± 0.30 72.1 ± 2.90 73.1 ± 3.14 74.0 ± 1.10 
11.0 80.1 ± 2.28 79.9 ± 0.57 75.4 ± 2.35 76.2 ± 3.28 76.9 ±1.12 
11.5 82.5 ± 1.76 82.0 ± 0.21 78.2 ± 1.64 80.0 ± 2.78 79.4 ± 0.35 
12.0 85.6 ± 0.68 84.0 ± 0.30 83.6 ± 1.51 82.5 ± 3.22 81.3 ± 0.36 
 TABLE: 7C- IN VITRO RELEASE DATA OF VALSARTAN FLOATING MATRIX TABLETS (F11 – F15) 
 
TIME IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* (n=3*) 
F11 (HPMC 
K15M 80%) 
F12 (HPMC 
K15M 75% + 
EC 5%) 
F13 (HPMC 
K15M 70% + 
EC 10%) 
F14 (HPMC 
K15M 65% + 
EC 15%) 
F15 (HPMC 
K15M 60% + 
EC 20%) 
0.25 24.1 ± 0.29 17.8 ± 0.38 19.1 ± 0.24 17.8 ± 0.29 21.5 ± 0.47 
0.50 25.8 ± 0.16 19.4 ± 0.18 21.5 ± 0.53 19.2 ± 0.57 23.2 ± 0.14 
0.75 27.2 ± 0.65 23.6 ± 0.89 24.5 ± 0.08 21.4 ± 1.22 25.4 ± 0.36 
1.0 29.3 ± 0.29 25.7 ± 0.56 27.0 ± 0.57 24.3 ± 0.74 27.6 ± 0.49 
1.5 30.9 ± 0.23 26.9 ± 0.57 30.0 ± 0.28 26.2 ± 0.29 29.9 ± 0.42 
2.0 32.5 ± 0.09 29.2 ± 0.49 33.4 ± 0.54 28.0 ± 0.73 32.5 ± 0.24 
2.5 34.2 ± 0.09 30.7 ± 0.36 35.5 ± 0.20 29.8 ± 0.98 35.8 ± 0.37 
3.0 35.8 ± 0.23 33.2 ± 1.53 37.8 ± 0.44 31.7 ± 1.07 37.7 ± 0.28 
3.5 38.1 ± 0.66 35.5 ± 1.51 39.1 ± 0.40 34.3 ± 1.09 39.4 ± 0.09 
4.0 40.3 ± 1.02 37.8 ± 1.45 42.0 ± 0.12 37.2 ± 0.98 41.6 ± 0.16 
4.5 42.3 ± 0.49 40.0 ± 0.54 43.8 ± 0.53 39.8 ± 1.43 43.8 ± 0.52 
5.0 44.3 ± 0.57 42.6 ± 0.57 45.5 ± 0.20 42.9 ± 0.84 45.5 ± 0.49 
5.5 47.5 ± 0.74 44.9 ± 0.53 47.6 ± 0.28 45.0 ± 0.66 47.1 ± 0.29 
6.0 51.0 ± 1.93 47.4 ± 0.37 50.1 ± 0.24 47.4 ± 0.24 48.4 ± 0.23 
6.5 54.1 ± 0.99 51.3 ± 0.47 52.1 ± 0.29 48.6 ± 0.45 51.0 ± 0.43 
7.0 56.5 ± 0.97 53.8 ± 0.45 53.4 ± 0.69 51.6 ± 0.30 52.8 ± 0.13 
7.5 58.9 ± 1.02 55.7 ± 0.38 56.7 ± 1.13 53.7 ± 0.16 54.8 ± 0.36 
8.0 61.2 ± 0.97 57.5 ± 0.59 59.2 ± 0.97 56.6 ± 0.60 56.1 ± 0.12 
8.5 63.5 ± 0.75 59.4 ± 0.73 61.0 ± 1.06 59.5 ± 0.20 58.4 ± 0.32 
9.0 65.9 ± 0.88 62.7 ± 1.92 63.1 ± 0.99 62.6 ± 0.57 60.7 ± 0.71 
9.5 68.4 ± 1.08 65.5 ± 1.03 65.7 ± 1.39 65.1 ± 0.57 62.5 ± 0.57 
10.0 71.1 ± 0.80 68.3 ± 1.63 68.2 ± 1.63 67.5 ± 0.86 64.9 ± 0.33 
10.5 73.2 ± 0.77 70.8 ± 1.82 71.0 ± 1.84 69.8 ± 0.14 67.5 ± 0.16 
11.0 76.0 ± 0.14 73.4 ± 2.14 73.1 ± 0.58 72.0 ± 0.89 70.4 ± 0.57 
11.5 78.2 ± 0.32 75.6 ± 1.48 75.6 ± 0.60 74.7 ± 0.59 73.5 ± 0.85 
12.0 80.6 ± 0.59 79.6 ± 0.75 78.6 ± 0.59 77.7 ± 0.68 76.6 ± 0.98 
 TABLE: 7D- IN VITRO RELEASE DATA OF VALSARTAN FLOATING MATRIX TABLETS (F16 – F20) 
 
TIME IN 
HOURS 
 
CUMULATIVE % DRUG RELEASE  ±  SD* (n=3*) 
F16 (MC 75%) F17 (MC 70% + 
EC 5%) 
F18 (MC 65% + 
EC 10%) 
F19 (MC 60% + 
EC 15%) 
F20 (MC 55% + 
EC 20%) 
0.25 19.6 ± 0.38 17.0 ± 0.80 15.6 ± 0.24 16.5 ± 0.38 17.3 ± 0.84 
0.50 22.5 ± 0.38 20.2 ± 0.54 18.2 ± 1.15 19.7 ± 0.52 19.2 ± 0.45 
0.75 25.0 ± 0.45 25.4 ± 0.31 22.1 ± 1.83 25.2 ± 0.42 21.8 ± 1.02 
1.0 27.0 ± 0.46 27.8 ± 0.36 25.6 ± 0.96 26.9 ± 0.36 24.3 ± 0.77 
1.5 30.4 ± 0.63 29.8 ± 0.28 28.2 ± 1.52 30.8 ± 0.20 26.6 ± 1.31 
2.0 33.6 ± 0.24 33.2 ± 0.47 30.7 ± 1.62 32.8 ± 0.26 28.8 ± 1.91 
2.5 35.2 ± 1.00 36.4 ± 0.29 34.5 ± 1.18 36.1 ± 0.38 31.2 ± 2.15 
3.0 39.1 ± 1.17 40.2 ± 0.41 36.4 ± 1.43 38.8 ± 0.57 33.0 ± 2.32 
3.5 41.2 ± 0.54 41.6 ± 0.16 39.5 ± 1.60 41.2 ± 0.28 35.8 ± 2.28 
4.0 44.2 ± 0.74 44.9 ± 0.16 42.0 ± 1.78 44.5 ± 0.29 38.3 ± 2.82 
4.5 45.2 ± 0.67 49.1 ± 2.40 45.2 ± 1.96 47.4 ± 0.57 40.8 ± 2.15 
5.0 46.8 ± 0.12 53.6 ± 1.66 48.1 ± 3.08 51.9 ± 0.74 43.4 ± 1.67 
5.5 48.5 ± 0.24 56.4 ± 1.60 51.6 ± 3.23 55.6 ± 0.40 45.5 ± 1.81 
6.0 51.2 ± 0.23 59.5 ± 1.46 55.8 ± 2.00 58.8 ± 0.42 47.3 ± 2.37 
6.5 53.6 ± 0.63 62.3 ± 1.65 58.4 ± 2.24 61.5 ± 0.67 50.9 ± 2.53 
7.0 57.0 ± 0.29 65.4 ± 1.17 61.1 ± 3.08 64.3 ± 0.20 54.0 ± 2.61 
7.5 60.1 ± 0.49 67.8 ± 1.12 64.2 ± 2.41 67.0 ± 0.37 57.1 ± 2.81 
8.0 62.7 ± 0.16 71.0 ± 1.58 67.1 ± 1.73 69.3 ± 0.49 59.9 ± 2.34 
8.5 65.9 ± 0.17 73.5 ± 1.38 69.8 ± 2.28 72.5 ± 1.05 62.7 ± 2.81 
9.0 68.8 ± 0.52 76.4 ± 0.75 72.2 ± 2.06 74.5 ± 0.49 65.9 ± 2.44 
9.5 72.1 ± 0.50 78.3 ± 1.58 74.4 ± 1.98 76.8 ± 0.26 68.9 ± 2.53 
10.0 75.1 ± 0.57 80.5 ± 1.38 76.7 ± 1.22 78.6 ± 0.22 72.1 ± 2.49 
10.5 77.9 ± 0.49 82.3 ± 0.75 78.9 ± 0.86 80.7 ± 0.46 74.6 ± 2.92 
11.0 83.0 ± 0.37 84.6 ± 1.58 81.8 ± 0.53 82.9 ± 0.17 78.6 ± 2.33 
11.5 86.8 ± 0.84 86.6 ± 1.11 84.2 ± 0.54 84.9  ± 0.37 80.8 ± 2.04 
12.0 90.3 ± 0.65 89.7 ±0.30 88.0 ± 0.71 87.8 ± 0.36 86.7 ± 1.24 
 
 TABLE: 8A- IN VITRO RELEASE KINETICS DATA OF VALSARTAN FLOATING MATRIX TABLETS (F1 – F10) 
FORMULATION 
CODE 
ZERO ORDER FIRST 
ORDER 
HIGUCHI KORSMEYER 
PEPPAS 
HIXSON 
CROWELL 
RELEASE 
MECHANISM 
r
2
 K
0 
(h
-1
) r
2
 K1 (h
-1
) r
2
 KH
 
(h
-1/2
) r
2
 n r
2
 
 
KHC (h
-1/3
) 
 
F1 0.977 2.382 0.954 -0.038 0.979 18.01 0.973 0.459 0.936 -0.107 NFD 
F2 0.969 2.325 0.941 -0.037 0.981 17.25 0.959 0.524 0.949 -0.104 NFD 
F3 0.969 4.490 0.943 -0.036 0.983 17.18 0.964 0.451 0.944 -0.101 NFD 
F4 0.945 4.113 0.930 -0.031 0.963 15.48 0.936 0.497 0.906 -0.089 NFD 
F5 0.993 3.855 0.965 -0.029 0.992 15.77 0.949 0.452 0.927 -0.087 NFD 
F6 0.963 5.524 0.942 -0.054 0.972 21.31 0.956 0.470 0.921 -0.142 NFD 
F7 0.967 5.613 0.953 -0.054 0.977 21.73 0.959 0.483 0.924 -0.144 NFD 
F8 0.979 5.618 0.935 -0.050 0.966 22.01 0.948 0.453 0.938 -0.137 NFD 
F9 0.976 5.566 0.948 -0.050 0.974 21.73 0.954 0.518 0.932 -0.137 NFD 
F10 0.965 5.381 0.961 -0.049 0.980 20.77 0.953 0.573 0.914 -0.133 NFD 
 
NFD- NON-FICKIAN DIFFUSION 
 
 TABLE: 8B- IN VITRO RELEASE KINETICS DATA OF VALSARTAN FLOATING MATRIX TABLETS (F11 – F20) 
FORMULATION 
CODE 
ZERO ORDER FIRST 
ORDER 
HIGUCHI KORSMEYER 
PEPPAS 
HIXSON 
CROWELL 
RELEASE 
MECHANISM 
r
2
 K
0 
(h
-1
) r
2
 K1 (h
-1
) r
2
 KH
 
(h
-1/2
) r
2
 n r
2
 
 
KHC (h
-1/3
) 
 
F11 0.959 5.138 0.955 -0.047 0.978 19.61 0.947 0.541 0.894 -0.126 NFD 
F12 0.970 5.249 0.960 -0.045 0.980 20.44 0.959 0.464 0.939 -0.118 NFD 
F13 0.970 4.995 0.953 -0.043 0.986 19.38 0.976 0.475 0.976 -0.122 NFD 
F14 0.973 5.219 0.967 -0.044 0.984 20.37 0.960 0.471 0.937 -0.122 NFD 
F15 0.966 4.632 0.941 -0.038 0.982 17.76 0.966 0.484 0.971 -0.107 NFD 
F16 0.966 5.820 0.887 -0.061 0.949 22.60 0.942 0.462 0.941 -0.156 NFD 
F17 0.970 6.306 0.967 -0.069 0.989 25.04 0.981 0.520 0.982 -0.173 NFD 
F18 0.976 6.178 0.961 -0.062 0.983 24.54 0.976 0.537 0.980 -0.079 NFD 
F19 0.976 6.164 0.966 -0.064 0.986 24.47 0.980 0.515 0.975 -0.165 NFD 
F20 0.978 5.772 0.919 -0.054 0.958 22.57 0.952 0.539 0.947 -0.146 NFD 
 
NFD- NON-FICKIAN DIFFUSION   
 
  
TABLE: 9 STABILITY STUDY (40
0
C/75% RH) OF BEST FORMULATION (F5) 
PARAMETERS 
INTERVALS OF TESTING (OBSERVATION) 
AT 0 MONTH AT 1
st
 MONTH AT 2
nd
 MONTH AT 3
rd
 MONTH 
Physical Appearance 
White colour, biconvex 
shaped 
White colour, biconvex 
shaped 
White colour, biconvex 
shaped 
White colour, biconvex 
shaped 
Hardness (kg/cm
2
) 4 4 4 4 
Diameter (mm) 10 10 10 10 
Thickness (mm) 4 4 4 4 
Friability (%) 0.28 0.27 0.25 0.24 
Weight variation (mg) 249.03 249.00 248.37 248.07 
Drug content (%) 99.79 99.20 98.70 98.00 
Floating lag time  Floats immediately Floats immediately Floats immediately Floats immediately 
Total floating time (hours) >24hrs >24hrs >24hrs >24hrs 
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